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Abstract 
Studies of the molecular mechanisms that are involved in stress responses (environmental or 
physiological) have long been used to make links to disease states in humans. The nematode 
model organism, Caenorhabditis elegans, undergoes a state of hypometabolism called the 
‘dauer’ stage. This period of developmental arrest is characterized by a significant reduction 
in metabolic rate, triggered by ambient temperature increase and restricted oxygen/ nutri-
ents. C. elegans employs a number of signal transduction cascades in order to adapt to these 
unfavourable conditions and survive for long times with severely reduced energy production. 
The suppression of cellular metabolism, providing energetic homeostasis, is critical to the 
survival of nematodes through the dauer period. This transition displays molecular mecha-
nisms that are fundamental to control of hypometabolism across the animal kingdom. In 
general, mammalian systems are highly inelastic to environmental stresses (such as extreme 
temperatures and low oxygen), however, there is a great deal of conservation between the 
signal transduction pathways of nematodes and mammals. Along with conserving many of the 
protein targets in the stress response, many of the critical regulatory mechanisms are 
maintained, and often differ only in their level of expression. Hence, the C. elegans model 
outlines a framework of critical molecular mechanisms that may be employed in the future 
as therapeutic targets for addressing disease states.   
Key words: Hypometabolism, Lifespan extension, Diapause, Post-translational modification, 
Transcriptional regulation, Apoptosis 
Introduction 
Metabolism is dynamic, and all living organisms 
must to respond to a wide variety of needs, signals 
and stresses in order to remain alive. Most often these 
responses adjust metabolism to meet new demands or 
to cope with internal or external stressors, but some-
times death responses are triggered to eliminate 
damaged or unneeded cells for the betterment of the 
whole organism. All organisms respond to many 
types of environmental stresses (e.g. heat/cold, oxy-
gen lack, desiccation, food limitation, etc.) with coor-
dinated adjustments to metabolism that deal with the 
consequences and/or injuries caused by the stress. In 
some cases, behavioural, physiological or biochemical 
adjustments are sufficient to adapt the organism to 
new conditions, and normal life can continue. How-
ever, when environmental stress reaches a critical 
level, organisms need to make choices. Death is usu-
ally not the preferred option, but sometimes one gen-
eration will take steps to ensure that the next genera-
tion has a better chance of survival. For example, short Int. J. Biol. Sci. 2010, 6 
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photoperiod and cooling temperatures cue females of 
various insect species such as silkworms to produce 
diapause eggs that can overwinter [1]. Embryos de-
velop for just a brief time, and then development is 
arrested (at the G2 phase of the cell cycle in silk-
worms) and the eggs transition into a dormant state 
called diapause where they can survive for many 
months until conditions are again favorable for the 
resumption of embryogensis [2]. Many other organ-
isms have comparable procedures; for example, brine 
shrimp shift from birthing nauplius larvae under fa-
vourable conditions to producing encysted gastrulae 
when environmental conditions are tough [3]. Em-
bryonic diapause (also called delayed implantation) 
also occurs in many other species including a variety 
of mammals where it allows mating to occur but de-
velopment to be delayed by arresting embryogensis 
until environmental conditions improve or until lac-
tation stops when a previous litter of offspring are 
weaned [4, 5].   
  Entry into a hypometabolic state, where meta-
bolic rate is strongly suppressed and normal activities 
are suspended, is actually a widespread response to 
stress across phylogeny providing organisms with a 
greater chance to survive through stressful times. As 
an example, entry into a dormant state where meta-
bolic rate falls to just 10% of normal resting rate pro-
vides an automatic 10-fold extension of the time that 
organisms can survive using only stored endogenous 
fuel reserves to support their energy needs. Such a 
time extension is typically more than enough to en-
sure survival through predictable seasonal periods of 
environmental stress particularly when paired with a 
strong enhancement of body fuel reserves in the 
weeks leading up to the entry into hypometabolism. 
Although only a minor part of the human experience 
[6], hypometabolism appears in many formats across 
the animal kingdom, as well as in plants and mi-
crobes. A hypometabolic state where metabolic rate is 
typically suppressed by at least 70% and in many 
cases to >95% or greater is a critical part of phenom-
ena including winter hibernation by mammals, 
nightly torpor by small birds and mammals, estiva-
tion and anhydrobiosis under summer drought con-
ditions, anaerobiosis in response to oxygen depletion, 
cold-hardiness and many other forms of dormancy or 
diapause (Selected reviews: [7 – 13]). 
 Known principles of hypometabolism are prov-
ing to be highly conserved across the animal kingdom 
and include (a) an overall strong suppression of 
metabolic rate, (b) differential control over the rates of 
individual metabolic processes so that energy use is 
reprioritized to favor core vital cell functions (e.g. 
maintenance of membrane potential difference) while 
largely shutting off “optional” activities (e.g. protein 
synthesis, cell division, growth and development), 
and (c) implementation of actions that protect cells 
and preserve viability over what could be many 
months of dormancy [12]. Actions that are important 
to life extension during dormancy can include chang-
ing to optimal patterns of fuel use (e.g. states of aes-
tivation or hibernation rely heavily on lipid reserves 
whereas anaerobiosis requires a switch to carbohy-
drate fuels), protecting and stabilizing cellular mac-
romolecules by enhanced production of chaperone 
proteins or antioxidant defenses, and implementing 
stress-specific actions such as colligative protectants 
that defend against cell water loss during freezing or 
drying. Furthermore, it is now clear from studies on a 
wide variety of animal systems of hypometabolism, 
that most of the molecular mechanisms of metabolic 
rate depression are highly conserved across phylog-
eny so that the principles of hypometabolism are be-
coming well-defined [12]. 
  Considerable research in recent years has de-
fined a number of critical molecular mechanisms that 
regulate transitions to/from hypometabolic states. 
Central among these is posttranslational modification 
of cellular enzymes and other proteins to provide 
coordinated transitions between high and low activity 
states. Reversible protein phosphorylation by the ac-
tion of protein kinases and protein phosphatases is by 
far the most widespread and potent mechanism con-
trolling hypometabolism, but in recent years, the im-
portant contributions  of a number of other post-
translational mechanisms are becoming increasingly 
recognized (e.g. methylation, acetylation, SUMOyla-
tion) (Selected reviews: [14, 15]). Research in recent 
years has also started to define mechanisms that 
regulate strong global suppression of transcription 
and translation while at the same time enhancing the 
expression of selected proteins with cytoprotective 
actions. Much research to date on hypometabolism 
has been concerned with energetics, fuel catabolism, 
and controls on energy-expensive cell functions such 
as controls on ion-motive ATPases, gene transcription 
and protein translation. Chaperones and antioxidant 
defenses are also frequent topics. Research progresses 
at a different pace and with different emphasis in 
model species of hibernation, estivation, anaerobiosis, 
etc. Overall, however, there is a growing interest and 
a move towards topics that include stress signaling 
(how are external stresses transduced and transmitted 
to regulate and coordinate thousands of cell func-
tions), reversible regulation of cell cycle, growth and 
development processes, the potential involvement of 
selective degradative processes (e.g. proteasome con-
trol, apoptosis and autophagy), and the mechanisms Int. J. Biol. Sci. 2010, 6 
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that stabilize/preserve cell viability to achieve 
long-term life extension in the hypometabolic state. 
Whereas these ideas are being analyzed at different 
levels and with different intensities in many different 
models of hypometabolism and are contributing to a 
unified theory of the principles of metabolic rate de-
pression, the question becomes – is there a model 
animal that we can use to provide insights into these 
new topics and help us lay the framework for ex-
panded studies of the principles of hypometabolism 
across phylogeny?  
 The answer is yes, and although the majority of 
scientists working on hypometabolism are interested 
in megafauna (e,g. hibernating mammals, estivating 
frogs, anoxia tolerant turtles, diapause in insects, etc.), 
it is to mesofauna that we need to turn for guidance 
on the new advances in understanding the regulation 
of hypometabolism. Specifically, the model is the 
nematode,  Caenorhabditis elegans. The remainder of 
this review will survey current information and ideas 
about the regulation of a form of stress-induced larval 
diapause in nematodes, called the dauer state. In 
conjunction with this, a focus will be placed on the 
mechanisms of the relatively inelastic 
(non-hibernating) mammalian system.  This com-
parative study will highlight conserved and con-
trasting molecular mechanisms that deal with stress 
states – both those that lead to tolerance of stress (C. 
elegans model system), and those that can result in 
disease/injury states (mammalian systems). 
The Insulin/ IGF Response Pathway: Stress 
Response and Dauer Regulation   
In the field of metabolic rate depression (MRD), 
one model that can experience numerous stress con-
ditions at once, in a period of stasis natural to its de-
velopment, is the nematode, C. elegans. As a model 
animal,  C. elegans, has become widely used due to 
several features including their genetic tractability, 
short generation time, ease of culturing, and a fully 
sequenced genome. This allows for gene disruption 
with relative ease, via knockouts or knockdowns 
(RNAi), providing for extensive studies on gene ex-
pression [16]. Under both natural environmental or 
lab culture conditions, C. elegans can be faced with 
stresses including overcrowding, limited food, ele-
vated temperature, increased desiccation and low 
levels of oxygen. Given that populations of these tiny 
organisms have little chance of dispersing themselves 
to a more hospitable environment, a primary response 
to stress is to enter a phase of arrested development, 
thereby postponing their entry into the reproduc-
tively mature stage until such time as conditions are 
more favourable [16]. This most widely characterized 
period of arrest occurs between the second and third 
stage of larval development, with the resulting 
nematodes becoming ‘dauer’ larvae. During this pe-
riod, the larvae do not eat and are extremely resistant 
to external conditions. As in all models of MRD, 
physiological changes reduce movement, respiration 
rate and digestion, while metabolic changes include a 
drastic reduction in ATP expenditure by altering 
critical metabolic processes. The oxidative stress im-
posed during dauer signaling conditions is one of the 
most critical to manage, and maintaining antioxidant 
defenses has been shown to significantly increase the 
lifespan of the nematodes [17]. In the dauer stage, 
larvae can survive up to ten times as long as 
‘non-dauer’ mature adults and are essentially ‘ageless’ 
in this period as it does not affect their post-dauer 
lifespan [16]. Under natural conditions, changes in 
environmental temperature (typically a rise) is per-
haps the most common signal for entry into dauer, 
with population factors (e.g. overcrowding, reduced 
sustenance) subsequently triggering the release of 
‘dauer promoting’ pheromones that lead to the for-
mation of dauer larvae. At the metabolic level, neu-
ronal signals are mediated through signaling path-
ways of ‘abnormal dauer formation’ (daf) genes; pre-
dominantly via the insulin response pathway [18].   
The insulin response pathway is initiated 
through insulin and insulin-like growth factor (IGF) 
signaling at the cell membrane through the insulin 
receptor and the insulin-like growth factor 1 receptor 
(IGF-IR). Mutations/deficiencies in these receptors 
are known to provoke lifespan extension in a number 
of animal models [19]. Downstream of the receptor, 
insulin receptor substrates (IRSs) and the phosphati-
dylinositol-3 kinase (PI3K) are also known to have 
conserved roles in lifespan determinacy [19]. The 
primary downstream target of these receptor targets 
is Akt (also known as protein kinase B). Akt has nu-
merous important downstream targets that are con-
served from C. elegans to humans, which can initiate 
survival responses throughout prolonged periods of 
environmental stress and can determine lifespan of 
the cell through regulating critical cellular processes. 
The Akt pathway has been particularly well-studied 
in the case of diabetes because it is responsive to in-
sulin, and is known to have downstream effects on 
glucose transport, protein synthesis, glycogen syn-
thesis, apoptosis and anti-apoptosis response path-
ways [20]. The exact mechanism of Akt activation 
initially involves the rapid conversion of the plasma 
membrane lipid, PIP2, to phophatidylinositol-3, 4, 
5-trisphosphate (PIP3), by PI3K, which causes PIP3 to 
become an active secondary messenger. PIP3 subse-
quently activates the 3’-phosphoinositide dependent Int. J. Biol. Sci. 2010, 6 
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kinase-1 (PDK1) (at the PH domain), which in turn 
phosphorylates and activates Akt, targeting the 
Pleckstrin homology in the Akt N-terminal region 
(Fig. 1) [21]. The key feature of this signal transduc-
tion is the phosphorylation of subsequent substrates, 
finally allowing active Akt to phosphorylate its nu-
merous downstream targets. The phosphorylation 
state of Akt, intuitively, is also the key point of regu-
lation, determining PI3K/Akt pathway activity or 
inactivity. Protein phosphatases, primarily the 
‘phosphatase and tensin homologue deleted on 
chromosome 10’ (PTEN) and protein phosphatase 2a 
(PP2A), act to suppress this signaling by removing 
phosphate groups from members of this pathway 
(Fig. 1). PTEN, more accurately a lipid phosphatase, 
targets the 3’ phosphate on PIP3, which was phos-
phorylated by PI3K, returning the messenger to its 
PIP2 state. Consequently, this prevents downstream 
activation of PDK1 and Akt. In conjunction with the 
role of Akt in cellular survival, development and pro-
liferation, deletions in PTEN have been shown to in-
duce tumors in mice, and in many mammalian can-
cers, PTEN is lost or mutated [22].  
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Figure 1: Summary of the insulin/IGF signaling pathway, using the terminology for mammalian systems. Binding of the ligand 
to the insulin like growth factor-I Receptor initiates the signaling cascade, which is propagated by PI3K. Akt acts as the 
signaling hub for the majority of the downstream effects such as cell cycle control, glycogen synthesis and apoptotic sup-
pression. The phosphorylation state of Akt is critically regulated by protein phosphatases (PTEN/PP2) and protein kinases 
(PDK-1). 
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Also acting to reduce the activity of Akt are 
members of the PP2 family of phosphatases. PP2A has 
long been known to regulate the phosphorylation 
state of Akt, but only recently has PP2B (also called 
calcineurin) been implicated in the same role [23]. 
Both phosphatases directly dephosphorylate active 
Akt, and have been thought to do so primarily in or-
der to promote the activity forkhead box transcription 
factors. Interestingly, in myocytes, FoxO activity con-
tains a feedback inhibition loop through the produc-
tion of the ubiquitin ligase, Atrogin-1, which targets 
calcineurin (PP2B) [23]. An alternative 
post-translational modification, the addition of 
O-linked β-N-acetylglucosamine (O-GlcNAc), is also 
known to inactivate PI3K downstream activity, likely 
by displacing phosphate groups on Akt.  
The relatively novel discovery that additions of 
O-GlcNAc to proteins is both ubiquitous and func-
tionally significant, has indicated that a number of 
signaling pathways may be modified, unbeknownst 
to researchers, by this mechanism [45]. Because of the 
small size, and uncharged nature of the molecule, 
detection of its addition to proteins is incredibly dif-
ficult, but its effects on phosphorylation state have 
made its responses discernable. This glycosylation 
consequently affects many critical procedures such as 
apoptosis regulation and cytoskeletal formation [45]. 
Addition of the molecule or ‘O-GlcNAcylation’, is 
mediated by the ‘O-GlcNAc-transferase’ (ogt), and 
reversed by O-GlcNAcase (oga). The mechanism 
whereby O-GlcNAc affects phosphorylation can be 
either direct, through competitive binding of phos-
phorylation sites, or indirect by binding nonspecific 
sites which affect the physical conformation of phos-
phorylation sites, reducing their accessibility. In terms 
of the Akt pathway, it was seen that 
O-GlcNAcylation, ogt targeting Ser473, prevented 
Akt phosphorylation and initiated apoptosis [46]; a 
process which typical Akt activity suppresses. This 
Akt inhibitory activity could also extend into the 
dauer model, given the importance of its regulation in 
pre-dauer conditions. Hence, the regulation of Akt 
phosphorylation state is critical to the success of the 
majority of PI3K signals (Fig. 1).   
Once active and released into the cytosol, Akt is 
able to commence signal transduction has targets af-
fecting numerous cellular processes and pathways, 
but typically promoting cellular survival and prolif-
eration. Downstream targets include glycogen syn-
thase kinase 3 (GSK-3), cell cycle regulators (p21, p27), 
protein synthesis (mTOR and TSC2, and subsequently 
P70S6K/ 4EBP) and cell survival factors (Bad, Fork-
head box transcription factors) (Fig. 1) [21]. Several of 
these targets are discussed next although discussion 
of mTOR is deferred to a later section. 
Regulation of the Forkhead Box transcription 
factors: 
Among the most important Akt targets are the 
members of the forkhead box family of transcription 
factors. In C. elegans, these are critical for entry into the 
dauer stage [24], and in stress-adapted animals, they 
have multiple and often conflicting responses when 
active.  The Forkhead Box family of transcription 
factors, also referred to as the Forkhead related 
(FKHR) transcription factors, are a highly conserved 
group across phylogeny with a number of subfami-
lies. Indeed, with in the subtype ‘other’ or FoxO, the 
mammalian proteins (often called FKHRs) and 
nematode proteins (called DAF-16) can substitute for 
each other; for example, mammalian FKHR (DAF-16a 
or FoxO1) and FKHRL1 (DAF-16b or FoxO3) have 
been used as transgenic substitutes for the DAF pro-
teins in C. elegans in order to initiate dauer formation 
[24]. FoxOs are increasingly recognized as an impor-
tant group of proteins in the regulation of cellular 
metabolism. Their activity is linked to oxidative stress 
responses, cellular proliferation and apoptosis path-
ways and they are one of the major known targets of 
the Akt pathway [25]. Through the PI3K/Akt path-
way, FoxO transcription factors are phosphorylated, 
which prevents their entrance into the nucleus, nulli-
fying their transcriptional activity. They may be 
phosphorylated on up to three sites by Akt, and in 
certain cases by serum-glucocorticoid kinase (SGK) 
(also activated by the PI3K pathway), which directly 
phosphorylates the nuclear localization signal (NLS) 
causing the recruitment of 14-3-3 binding proteins 
(Fig. 2) [17]. Signaled by the phosphorylated residues 
(particularly serine), the 14-3-3 protein binds the FoxO 
transcription factor, obstructing its NLS, preventing 
nuclear (re)entry and changing FoxO conformation to 
expose its NES, which if the transcription factor is in 
the nucleus, causes its expulsion [26]. Regardless of 
the original nuclear/cytoplasmic location, prior to 
phosphorylation, binding of the 14-3-3 protein an-
chors the transcription factor in the cytoplasm, and is 
also suspected of inhibiting any DNA binding activ-
ity, due to the location of 1 4-3-3 binding which is 
proximal to the FoxO DNA binding domain (Fig. 2) 
[26]. Hence phosphorylation of FoxOs is the primary 
means of their transcriptional regulation.  
 Int. J. Biol. Sci. 2010, 6 
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Figure 2: Regulation and downstream targets of the forkhead box (subtype O) transcription factors. Protein kinases (Akt and 
SGK) phosphorylate FoxO on up to three sites, including one proximal to the nuclear localization sequence (NLS). This 
prevents nuclear translocation or, in the event that the FoxO is phosphorylated in the nucleus, nuclear expulsion. Phos-
phorylation may stimulate binding of the 14-3-3 protein to the transcription factor, covering its NLS and DNA binding 
domains and blocking transcriptional regulatory capacities. 
 
In mammals, FoxO activity is strongly linked 
with apoptosis through its interactions with 
pro-apoptotic genes including BCL6 and BIM, but 
may also initiate apoptosis through cell cycle arrest 
(Fig. 2) [27]. Mammalian FoxOs up-regulate tran-
scription of the ‘eukaryotic initiation factor 4E binding 
protein (4EBP), a protein that binds to the eukaryotic 
initiation factor 4 (eIF4e), preventing its interaction 
with other members of the translation initiation com-
plex [27]. This can force cell cycle attenuation and 
possibly trigger apoptosis signaling. Hence, in some 
contexts, phosphorylation of FoxOs can be seen as an 
anti-apoptosis response. This however, reveals the 
contradictory nature of FoxO signaling, with other 
targets of FoxO transcriptional regulation being pro-
tective (even pro-survival) in nature. For example, 
FoxOs are known to regulate the expression of anti-
oxidant enzymes such as manganese superoxide 
dismutase (MnSOD) and catalase that have key roles 
in protecting cells from the damaging effects of reac-
tive oxygen species (ROS). This duality in the FoxO 
family role under stress may be a result of non-AKT 
mediated posttranslational phosphorylation of the 
FoxOs, or modification by other means such as ace-
tylation [25]. 
Regulation of Glycogen Synthase Kinase: 
Another critical target of the Akt pathway is 
GSK-3 through which AKT mediates the stimulation 
of glucose uptake and glycogen synthesis. Glycogen 
synthesis is regulated in part by GSK-3 which phos-
phorylates glycogen synthase, inactivating it and 
preventing the conversion of UDP-glucose to glyco-
gen. GSK-3 is composed of α and β subunits, both of 
which can be phosphorylated by Akt [20]. The inter-
action between Akt and GSK-3 has yet further reper-
cussions, although Akt maintains its 
pro-developmental role in allowing glycogen synthe-Int. J. Biol. Sci. 2010, 6 
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sis (Fig. 1). Akt phosphorylation of GSK-3 can also 
relieves GSK-3 inhibition of protein synthesis at the 
eukaryotic initiation factor 2 (eIF2) locus and at the 
level of mTOR complex formation. This allows for 
increased protein synthesis and cell proliferation [28].   
Active GSK-3 can also phosphorylate eIF2B to inacti-
vate it, and as such, the Akt repression of GSK-3 ac-
tivity prevents this. Briefly mentioned before was the 
interaction between Akt and mTOR, in which Akt 
contributes to mTOR activation; GSK-3, via Akt, may 
also contribute to the activation of mTOR. GSK-3, 
acting on the mTOR activating complex TSC1/2, is 
able to phosphorylate, and contribute to its activity, 
which in turn, negatively regulates mTOR complex 
formation [28].  This continues to correspond with 
the conflicting pro-development (Akt)/ development 
attenuation (GSK-3) relationship, which may be a di-
rect link to the mTOR complex 1’s (mTORC1) ability 
to increase ribosomal DNA transcription, which in-
dicates increased ribosomes; allowing for increased 
protein synthesis and cell proliferation [28]. 
A further role of GSK-3 is in the regulation of cell 
death via c-Myc inhibition. By inactivating c-Myc, 
GSK-3 inhibits the induction of Bax and Bim 
(pro-apoptotic members of the Bcl-2 family) among 
other c-Myc activated apoptosis targets (Fig. 1) [29]. 
Furthering its role in apoptosis inhibition, the absence 
of GSK-3 subsequently alters glucose metabolism, 
specifically resulting in the dissociation of hexokinase 
II from the mitochondrial membrane causing its in-
stability [29]; mitochondrial membrane integrity is 
one of the key factors in cell death regulation (see later 
section on apoptosis).  Contrary to typical Akt re-
sponses that support cell development, division and 
survival, this would seem to allow apoptotic stimula-
tion through c-Myc activity in a system with active 
Akt. However, c-Myc can be consequently down 
regulated through a convoluted system which in-
volves P13K/Akt activation of E2F transcription fac-
tors [30] to regulate and counteract c-Myc apoptotic 
signaling. The relationship between E2F and c-Myc 
involves both members regulating each other, and as 
such, is likely dependent on other factors that will not 
be discussed here. Also to be taken into consideration 
is the role of c-Myc in cell cycle progression, through 
suppression of p15, p21 and p27, to allow transition 
through G1 into the S phase (Fig. 1) [31]. It is in this 
mechanism that Akt-based suppression of GSK-3 (and 
resultant c-Myc activity) appears to correspond best 
with the general pro-development role of Akt.    
Regulation of the cell cycle through Akt: 
Akt also has numerous targets affecting the cell 
cycle, one of which, cyclin D, is also a target of GSK-3. 
In this case, active GSK-3 is able to phosphorylate 
cyclin D, preventing it from further interacting with 
cyclin dependent kinase 4 (CDK4) [31]. In terms of the 
cell cycle, the binding of cyclins to CDKs is essential to 
the formation of maturation promoting factors 
(MPFs), which regulate events such as microtubule 
formation, which allows for cellular division. Forma-
tion of these complexes in the nucleus is critical to the 
progression of the cell cycle past the G1 phase into the 
S phase, and it is here that Akt exhibits the majority of 
its cell cycle effects. Two inhibitors of cell cycle pro-
gression, p21 and p27, both of which can prevent the 
formation of the cyclin E/CDK2 complex, can be 
regulated by phosphorylation. Akt is capable of 
phosphorylating both at their NLS sites, which an-
chors them in the cytoplasm [31] preventing interac-
tion with cell cycle proteins. In addition, p27 is a tar-
get of the FoxO transcription factors, and through Akt 
phosphorylation (preventing nuclear translocation), 
Akt is also able to down regulate the transcription of 
p27 (Fig. 1 and 2) [31]. While regulation at the G1/S 
phase is widely regarded as the control centre of cell 
cycle progression, the exit from cell cycle (M phase) 
into the quiescence phase (Go) is also a critically 
regulated step, and is also a target of Akt signaling.  
The retinoblastoma family member, p130 (Rb2), 
is critical in signaling the exit from the cell cycle and is 
positively (transcriptionally) regulated by FoxO 3a 
[32]. While FoxO activity is negatively regulated (by 
Akt) to allow cell cycle progression, preventing its 
role in enhancing cell cycle attenuator (p27) tran-
scription, it is seen to be active in the M phase of the 
cell cycle in order to promote its exit. At this stage, 
p130 is transcriptionally up-regulated and activated 
by cyclin/CDK (typically D/4) phosphorylation, 
which may release it from an E2F4 negative inhibitor 
[32]. Hence the relationship between Akt and the 
FoxOs appear to mediate the switch between cell cycle 
exit (down regulation of Akt activity) and cell cycle 
re-entry/progression (up-regulation of Akt activity).  
In contributing to the control of critical cellular 
processes such as cell cycle and energy storage, Akt, 
like many other kinases is heavily involved in stress 
responses. These responses typically involve the al-
teration of metabolic process in order to maintain en-
ergetic homeostasis of the cell. Along with Akt, one of 
the major (if not the primary) energy metabolism 
regulators are the AMP-activated protein kinase 
(AMPK) family of protein kinases. They are involved 
in various and multiple metabolic processes (includ-
ing glycolytic control, glucose transport etc.), and are 
triggered by a diverse range of metabolic stressors, 
including hypoxia, heat shock and nutrient deficiency 
[33]. AMPK, as well as being stimulated directly by Int. J. Biol. Sci. 2010, 6 
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AMP (a marker of low energy status), must be phos-
phorylated (at Thr 172, typically by LKB1) before be-
coming activated. The AMPK-related kinase (ARK5) 
member of this family is activated by Akt phos-
phorylation, which is thought to be part of an 
Akt-mediated response to nutrient starvation (Fig. 1) 
[33]. Subsequently, ARK5 can phosphorylate the tu-
mor suppressor, ‘ataxia-telangiectasia’ kinase (ATM), 
which is a member of the PI3K family. ATM, in turn, 
phosphorylates the tumor suppressor transcription 
factor, p53, which stabilizes and activates it, leading to 
downstream apoptotic signaling [33]. This indicates a 
contradictory response in Akt signaling, since the 
general consensus of Akt signaling appears to support 
cellular survival and development. 
Regulation of the Insulin response pathway from 
a C. elegans perspective: 
As mentioned above, the nematode C. elegans can 
enter a period of arrested development known as the 
dauer stage, when faced with stresses such as over-
crowding, lack of food and substantial changes in 
temperature. Initial studies on the mutation of insulin 
response genes revealed that when members of the 
canonical IGF/PI3K/Akt pathway were mutated, 
dauer larvae were formed (Fig. 3). These were the 
daf-2 (abnormal dauer formation), age-1 and akt-1/2 
genes [34]. Daf-2 encodes the tyrosine kinase receptor 
which binds insulin and other growth factors on the 
plasma membrane, and activates itself through 
auto-phosphorylation. AGE-1 (equivalent to mam-
malian PI3K) is recruited to produce PIP3 as an acti-
vator of downstream kinases, in order to propagate 
the insulin/IGF signaling [34]. It has been suspected 
that, even with the mutations in daf-2 and age-1, dauer 
formation may still be inhibited, through an inde-
pendently activated AKT-1/2 (C. elegans Akt ho-
mologs – functionally redundant) pathway. As in the 
mammalian system, the DAF-2 pathway follows the 
canonical activation of AKT via AGE-1(PI3K) and a 
3-phosphoinositide dependent kinase (PDK) ho-
molog. Any inhibition up until the phosphorylation of 
AKT-1/2 typically results in DAF-16 (C. elegans fork-
head box transcription factor homolog) mediated en-
try into the dauer state (Fig. 3) [35]. The recently dis-
covered importance of the C. elegans PDK-1 in AKT 
activation indicates a further level of regulation in the 
DAF-2 pathway, and like its mammalian homolog, 
affect other critical development targets (such as 
p70S6K, discussed later) which affect lifespan and 
dauer entry [35]. Hence it is suspected that AKT, and 
to a lesser extent PDK-1, may be able to inhibit dauer 
formation through the phosphorylation of the DAF-16 
transcription factors, even in the absence of functional 
daf-2/age-1 [36]. This is the result of PDK-1 being 
constitutively active under basal conditions and re-
maining active (even at low levels) to activate AKT 
[36]. Through this path, regulation of AKT, which 
directly affects DAF-16, is critical in controlling the 
switch between development into the reproductively 
mature state, or entry into the quiescent dauer phase. 
As in mammalian systems, C. elegans AKT regu-
lates the FoxO homolog, DAF-16, via phosphoryla-
tion, inhibiting its ability to move into the nucleus. 
The C. elegans FoxO also shares many of the mam-
malian downstream target genes, which are necessary 
for entry into and sustaining the dauer state (Fig. 3). 
DAF-16 activity centers on the attenuation of the cell 
cycle (affecting proteins such as p27, p130 and 4EBP) 
that categorizes the dauer stage of stasis [17]. The 
self-imposed production of antioxidants (MnSOD and 
catalase) in anticipation of oxidative stress, is also 
critical. In fact, minimization of oxidative stress is of 
such importance that, as in the mammalian system, 
the MnSOD homolog (sod3 in C. elegans) is regulated 
directly by DAF-16. FOXO3 has a consensus site in the 
MnSOD promoter region, and it is suspected that 
similarly, DAF-16 and sod3 are related, in order to 
trigger the activity of this mitochondrial antioxidant 
[37]. Hence, regulation of DAF-16 nuclear entry, 
critically affects whether the nematode will not only 
enter the dauer stage, but be able to endure the ener-
getic and oxidative limitations imposed on it during 
this phase, in order to proceed into maturity. 
One of the main physical responses to C .elegans 
prior to dauer entry (the ‘pre-dauer’ stage), is the ac-
cumulation of lipid stores, to provide a source of en-
ergy to endure the dauer stage. Hence, it could be 
suspected that DAF-16 has downstream targets that 
regulate fat metabolism during the dauer stage, in 
order to ration energetic expenditure. One possible 
target is the pantothenate kinase (C. elegans  pnk-1), 
which is involved in coenzyme A synthesis (a key 
member of fat metabolism). In cases of inhibited 
DAF-2 signaling (as would occur during the dauer 
stage), pnk-1 is up-regulated, and fat storage levels are 
reduced, possibly indicating it as a target of DAF-16 
[37]. This may be related to AMPK based responses, 
due to AMPK’s role in the regulation of fat storage 
consumption rates (briefly elaborated upon in the 
TOR section).  
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Figure 3: Insulin/IGF signaling in C. elegans controls entry into the dauer larval stage. Dauer entry is prevented through AKT 
mediated phosphorylation of the DAF-16 (FoxO homolog) transcription factor. Like the mammalian model, AKT phos-
phorylation is the key to canonical DAF-2 signaling, and is regulated by protein kinases (PDK-1) and phosphatases (DAF-18 
and PPTR-1). 
 
The key regulatory switch, it seems, is the 
phosphorylation state of AKT. As in mammalian sys-
tems, dephosphorylation via protein phosphatases 
(primarily PTEN, known in C. elegans DAF-18) is es-
sential to inhibit DAF-2 signaling (Fig. 3). The DAF-18 
phosphatase not only mediates dauer entry through 
the suppression of AGE-1 activity, but also contrib-
utes to an earlier quiescent phase. Post hatching, and 
prior to feeding, the C. elegans larvae are in their L1 
phase, and will often enter a quiescent stage until nu-
trients are available [38]. Thus, it is through DAF-2 
signaling, specifically with DAF-18 inhibiting AGE-1 
signaling that the L1 larvae are able to go into dia-
pause [38]. Along with PTEN phosphatase, it has re-
cently emerged that the PP2A catalytic subunit 
(PPTR-1) may also contribute to C. elegans dauer 
regulation, acting directly on AKT-1 [39]. Active AKT 
requires phosphorylation in its activation loop, typi-
cally by PDK-1, but may also be phosphorylated by a 
TOR complex. PPTR-1 acts d i r e c t l y  o n  A K T - 1 ,  b u t  
interestingly not AKT-2 or SGK-1 (the C. elegans SGK 
homolog, which may also phosphorylate DAF-16), 
both of which are phosphorylated when active, in-
creasing lifespan through DAF-16 mediated dauer 
entry [39]. Regulation of AKT by PP2A in the mam-
malian system also reflects this (mentioned above), 
with the B56 family of subunits being the mammalian 
PPTR-1 homologs which are critical to PP2A forma-
tion.  Also preventing the pro-developmental aspect 
of AKT signaling, B56 deficiency is a characteristic of 
numerous tumors. B56 isoforms also regulate the tu-
mor suppressor p53, which furthers their role in tu-
mor suppression [39]. Hence, the role of the PP2A 
subunits appears conserved between C. elegans and 
mammalian systems, in their anti-AKT activities 
which prevent excessive cellular energy expenditure 
and proliferation.  
However, it is not only phosphatases that affect 
AKT in order to increase DAF-16 activity. The c-Jun 
N-terminal kinase (JNK) is involved in many stress Int. J. Biol. Sci. 2010, 6 
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response signaling cascades, and previously in 
mammalian systems, has been shown to interact with 
the IGF pathway (Fig. 3). A JNK upstream kinase 
(JKK) knockout inhibits C. elegans lifespan extension, 
indicating a positive role for JNK in dauer expression 
[40].  Interestingly, JNK positively regulates DAF-16 
through phosphorylation (which is typically an in-
hibiting factor).  In this case, phosphorylation ap-
pears to contribute to signaling DAF-16 for nuclear 
translocation, making it a unique response to stress 
signaling in C. elegans lifespan extension [40]. This 
activity of JNK in supporting lifespan extension may 
be in conjunction with an AKT interaction with the 
‘JNK interacting protein 1’ (JIP1). This protein, which 
regulates JNK activity in mammalian systems, acting 
as a scaffold protein (aiding phosphorylation of target 
proteins) is crucial. In this context, the JIP1 protein 
may act as a scaffold protein for both AKT and JNK, 
assisting both in their enzymatic activities [41]. Hence, 
a competition forms for binding with this co-factor, 
between AKT and JNK. JNK requires both phos-
phorylation and JIP1 binding to become active. Bind-
ing of AKT to JIP1 may actively prevent JNK activa-
tion of DAF-16, while increasing its own capacity to 
inhibit DAF-16. 
Supplemental to the IGF pathway, which acts 
primarily through PI3K/Akt activity, are a number of 
insulin receptor substrates and adaptors which can 
help to propagate the insulin response signals, or in-
deed, signal secondary pathways through insulin re-
ceptor activity. In C. elegans, this may result in an al-
teration in dauer signaling, with DAF-2 activity cen-
tral to its regulation. The insulin receptors (typically 
tyrosine kinases) phosphorylate downstream ‘insulin 
receptor substrates’ (IRSs), such as the aap-1 PI3K 
adaptor subunit which attaches to the catalytic sub-
unit, and the IST-1 IRS, which may also aid in forma-
tional function of AGE-1 [42]. While these two ele-
ments are not absolutely essential for IGF signaling, 
they are required for full DAF-2 activity. Although 
mutations in both still resulted in DAF-2 signaling, as 
revealed through levels of DAF-16 protein expression 
(and resulting numbers of dauer larvae), it is sus-
pected that in conjunction with mutations of more 
critical members of the pathway (AGE-1 and AKT), 
dauer arrest was enhanced [42]. This also opens up 
the possibility of alternate DAF-2 signaling, possibly 
via homologs of mitogen-activated protein kinases 
(MAPKs).  
Whereas the dauer stress response is the most 
explored, analysis of C. elegans responses to oxidative 
stress has also revealed a number of targets and re-
sponses that are less studied, but possibly contribute 
to dauer survival (Fig. 3). Oxidative stress, and its 
critical role in aging, has made the study of its re-
sponse elements critical in such fields as diabetes and 
cancer research. One of the primary targets in protec-
tive responses against oxidative damage (ROS based) 
is the SKN-1 transcription factor [43]. This transcrip-
tion factor targets ‘phase II’ detoxification genes such 
as SOD and Glutathione-S-Transferase (GST), which 
are antioxidant enzymes, preventing oxyradical 
damage to membranes and DNA [43]. The SKN-1 
protein is a C. elegans homolog of the mammalian 
NF-E2 related factor (Nrf) family, which is also a 
critical oxidative response element, and is regulated 
both positively and negatively by phosphorylation. 
Under normal conditions, when SKN-1 activity is not 
necessary, it is anchored in the cytoplasm by gsk-3 (C. 
elegans GSK-3 homolog) mediated phosphorylation 
(likely at Ser-393) [43]. Under conditions of oxidative 
stress, however, the p38 MAPK ortholog (PMK-1), as 
in mammalian systems, begins its stress response 
cascade by phosphorylating and activating SKN-1 as 
one of its targets [43]. The SKN-1 transcription factor 
may also be activated by a number of less 
well-documented stress response kinases such as the 
NEKL-2 (mammalian NEK-8)and IKKε-1(mammalian 
NF-κB inhibitor) kinases, involved in cell cycle regu-
lation and host immunity, respectively [44]. Survival 
duration, in response to oxidative stress, drops dras-
tically in the absence of these particular kinases, likely 
indicating that their roles are critical process regula-
tors, aside from their interactions with SKN-1 [44]. 
However, their role in SKN-1 activation may be more 
dominant than expected, when looking at the role 
AKT plays in this pathway. Under typical dauer con-
ditions, of which one of the contributing factors is 
oxidative stress, AKT is suppressed, allowing 
DAF-16, and more pertinently, GSK-3 activity. This, 
hypothetically, would result in negative regulation of 
SKN-1 in a period where it would likely need to be 
active.  
Transforming Growth Factor β Signaling:    a 
Role in Dauer Regulation   
The transforming growth factor β (TGF-β) sig-
naling pathway is involved in both proliferation and 
cell differentiation. It responds to neuronal signaling, 
which is in turn responsive to external signals in-
cluding environmental cues. The TGF-β pathway has 
parallels with the Insulin/IGF pathway and its ex-
pression is also typically seen under conditions con-
ducive to growth that involve considerable energy 
expenditure. Pro-TGF-β signaling has been implicated 
as a component and target of tumorigenesis. TGF-β 
signaling and its role in cancer signaling is well Int. J. Biol. Sci. 2010, 6 
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known to be paradoxical, with apparent functions in 
both cell cycle attenuation/apoptosis and the promo-
tion of tumor formation. It is still unclear as to how 
the switch in activity is made, but in different types of 
cancer, increased TGF-β production and downstream 
Smad dependent activity are seen to induce tumori-
genesis. Consequently, anti-TGF-β responses can be 
partially classified as anti-proliferative or 
anti-developmental. 
The TGF-β superfamily in mammals is a large 
and varied grouping of growth factors and develop-
mental elements, which include the TGF-β ligands as 
well as ‘bone morphogenic proteins’ (BMPs), activins 
and ‘growth and differentiation factors’ (GDFs). The 
general pathway of signaling involves ligand binding 
at the cellular receptor (serine/threonine kinase re-
ceptors), followed by activation and downstream 
messaging via the ‘mothers against decapentaplegic’ 
(Smad) family of transcription factors [47]. In mam-
malian systems, the ligands require dimerization be-
fore binding and activating the type II receptor. The 
ser/thr kinase receptors must complex in order to 
initiate downstream signaling, with the type II re-
ceptor able to recruit the type I receptor, after inter-
acting with the ligand (Fig. 4) [47]. The type II recep-
tor, which has higher affinity for ligands, has the ca-
pacity to autophosphorylate, which is likely a critical 
factor in its own activation as well as subsequent ac-
tivation of the type I receptors (via phosphorylation) 
[48]. There are multiple type I (designated ALK1-7) 
and type II receptors which provide specificity to both 
different ligands (upstream via the type II receptor), 
and different Smads (downstream via the type I re-
ceptor) [48]. Regulation of the phosphorylation state 
of the type I receptor’s is critical to the success of 
TGF-β signaling, and there are numerous interactions 
with the receptor which can lead to its activation or 
can facilitate its inactivation/degradation. One such 
inhibitory interaction is with the prolyl isomerase 
FKBP12 protein.  FKBP12 can bind the type I recep-
tor, and through structural changes, make it unable to 
interact with the type II receptor (Fig. 4) [48]. 
De-phosphorylation of the type-1 receptor is another 
common mechanism of TGF-β inhibition, with phos-
phatases such as PP2A (although, specifically the Bδ 
subunit) targeting the type-I receptor. Disabling the 
receptors prevents signaling of the major downstream 
targets of the TGF- β pathway, the Smad transcription 
factors [48].  
The primary effectors of TGF- β signaling, the 
Smad transcription factors:  
Downstream of the TGF-β receptor kinases is the 
Smad family of transcription factors. In mammals, 
Smads are categorized in three types: receptors (Smad 
1,2,3,5 and 8) that require double phosphorylation in 
order to become active and translocate into the nu-
cleus, complexing (Smad 4), and inhibitory (Smad 6 
and 7) [47]. Phosphorylation of the receptor (r-) Smads 
can either activate or inhibit the transcription factors, 
depending on where the protein is phosphorylated. 
The SXS motif at the C-terminal is critical to Smad 
activity, with double phosphorylation at this site 
necessary, prior to complexing and entry into the nu-
cleus [48]. Active r-Smads, forming complexes with 
themselves (Smad2/3 and Smad1/5/8) or remaining 
monomeric (typically Smad 2), will further complex 
with Smad 4 and move into the nucleus (Fig. 4) [47]. 
Another means of moving into the nucleus is to com-
plex with other transcription factors, relying upon 
their nuclear localization sequences (NLSs) in order to 
move out of the cytoplasm. An example of this is the 
Smad 2 interaction with the tumor suppressor p53, 
activated upstream by a receptor tyrosine kinase [47]. 
Once in the nucleus, Smad complexes are able to bind 
TGF-β promoter elements, and in some instances 
(with the Smad2/3), bind co-factors such as TAZ or 
p300 (also a p53 co-factor) which stabilize the complex 
and partially prevent nuclear expulsion (Fig. 4). The 
primary member of Smad signaling is Smad 2, which 
can, but does not require homodimerization with 
other r-Smads (although it still requires conjunction 
with Smad4). Its phosphorylation and presence in the 
nucleus is a significant indicator of successful TGF-β 
signal transduction [47]. Smad 2 activation may also 
be increased by an interaction with the ‘Smad anchor 
for receptor activation’ (SARA), which in complexing, 
relocates the Smad to the type I receptor for phos-
phorylation [48].  
Mentioned above, the phosphorylation of Smads 
can also lead to their inability to complex and enter 
the nucleus, and in the cases of complexes already in 
the nucleus, their expulsion and subsequent degrada-
tion. The linker region is a fairly unconserved region 
sandwiched between two ‘MAD homology’ (MH1 
and 2) domains and, like the SXS region, is susceptible 
to phosphorylation. Unlike the SXS domain, phos-
phorylation at the linker site is known to decrease 
Smad transcription factor activity and is mediated by 
a series of kinases implicated in anti-proliferative and 
stress response procedures. The cyclin dependent 
kinases (CDKs), GSK-3, and MAPKs including ERK 
and JNK, which can all show anti-proliferative or en-
ergy conservation roles, can phosphorylate the linker 
sites of Smad proteins [48]. In the cytoplasm, phos-
phorylation of linker sites is linked to ubiquitin ligase 
mediated degradation of the proteins, whereas in the 
nucleus it leads to Smad expulsion (Fig. 4). The deg-Int. J. Biol. Sci. 2010, 6 
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radation response that is mediated by E3 ubiquitin 
ligases (Smurf 1 and 2) appears to be almost exclu-
sively signalled by phosphorylated residues on the 
Smad proteins, which not only implicates linker 
phosphorylation, but likely the SXS motif phos-
phorylation as well [48]. The primary targets for this 
activity are Smad 1, Smad 4 and the Smad2/3 com-
plex [48]. The nuclear expulsion response can be 
regulated in at least two ways. One is dephosphory-
lation of the complexes, which can be accomplished 
by several phosphatases. Interestingly, the protein 
phosphatase PPM1A, which can directly bind phos-
phorylated Smad2/3 complexes and promote their 
nuclear expulsion, may be stabilized by the PTEN 
phosphatase [48]. An alternate means of expulsion 
affects Smad 4 which is exported after sumoylation of 
the protein [47].    
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Figure 4: TGF-β signaling in mammalian models. Signaling begins with ligand dimerization and interaction with the type II 
receptor. This recruits and activates (via phosphorylation) the type I receptor. The active type I receptor phosphorylates 
downstream Smad transcription factors, which form complexes and enter the nucleus. There are numerous inhibitory 
pathways that act on both the type I receptor, and the Smad transcription factors, typically resulting in loss of phos-
phorylation state or ubiquitin ligase mediated degradation. 
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Negative regulation of the TGF- β pathway 
through inhibitory Smads: 
Whereas the r-Smads are the primary effectors of 
the TGF-β pathway, the inhibitory Smads, which rely 
on protein-protein interaction more so than transcrip-
tional activity, play a large role in regulating r-Smad 
signaling. As part of this role, the inhibitory Smad7 
may mediate direct type I receptor degradation 
through the recruitment of the ubiquitin ligases 
Smurf1/2. This particular degradation signal may 
also be enhanced by the binding of FKBP12 to the 
receptor (mentioned above), with a subsequent inter-
action between the Smad7-Smurf-1 complex aiding 
ubiquitination of the receptor (Fig. 4) [48]. Along with 
degradation, Smad 7 is able to prevent type I receptor 
signaling through dephosphorylation. Recruiting 
protein phosphatase 1 (PP1), through an interaction 
with GADD34, Smad 7 is able to prevent downstream 
phosphorylation of the pro-TGF-β Smads [47]. While 
the role of PP1 here is to inactivate Smad phosphory-
lation via the receptor, it is also capable of preventing 
Smad 2 phosphorylation through binding (inactiva-
tion) of the SARA protein that facilitates relocation of 
the Smad to the receptor [48].  
As a protective mechanism, degradation of the 
receptors, signaled through Smad 7-Smurf-1/2 inter-
actions, can be partially compensated for if the re-
ceptors bind the heat shock protein, HSP 90, which 
maintains receptor structure, preventing ubiq-
uitin-mediated degradation [48]. The inhibitory 
Smads may act as a feedback mechanism during ex-
cessive TGF-β signaling, or may become active de-
pendent on the developmental stage of the cell. 
The pro-development, anti-dauer TGF- β path-
way in C. elegans: 
The TGF -β pathway in C. elegans is one of the 
major signaling pathways associated with entry into 
the dauer stage, and is often thought of as a parallel 
system to the the insulin/IGF pathway, although 
secondary path to it. Like the insulin response/IGF 
pathway, the active TGF-β pathway acts to suppress 
entry into the dauer stage [18]. The TGF-β pathway 
functions through ligand binding to cellular receptors; 
type I (DAF-1) and type II (DAF-4) (Fig. 5). This sys-
tem purports cell-cell communication and eventual 
signal transduction, which could lead to a consensus 
event; of importance in the context of C. elegans, entry 
into dauer [49]. In this sense, the parallel pathway of 
Insulin/IGF signaling, which is also cell receptor 
based, may produce converged signals through cel-
lular cross-talk, in order to suppress dauer entry. 
Downstream of the cellular receptors is the TGF-β 
(DAF-7) protein which in turn regulates production of 
downstream Smads. The Smads must be phosphory-
lated to become active, which in the case of pro-TGF-β 
Smads is done at the cellular receptor complex (via 
DAF-1) followed by entry into the nucleus. Phos-
phorylation activation of the Smads, as in mammal 
systems, occurs at the C terminal, but while it has not 
been studied in depth, some phosphorylations of C. 
elegans Smads can result in a reduction of expected 
Smad responses [50]. This is a possible indication of 
linker site regulation, used to negatively regulate 
TGF-β signaling.  Once in the nucleus, the pro-TGF-β 
Smads are able to stimulate the transcription of genes, 
but they are also capable of acting in protein-protein 
complexes as cofactors for each other, to prevent 
dauer signaling [49]. Pro-dauer signaling is also, in-
terestingly, mediated by Smad proteins. Hence, the 
Smads can be divided into pro- (DAF-3/5) and anti- 
(DAF-8/14) dauer members, with the anti-dauer 
members acting upstream of the pro-dauer members 
to regulate dauer entry. During successful TGF-β 
signaling, a relationship forms where DAF-8/14, 
through directly inhibiting DAF-3/5 in the nucleus, 
prevents dauer entry (Fig. 5). In experimental condi-
tions, it has been shown that DAF-3 mutants are un-
able to form dauer larvae, and as such, have a severely 
reduced lifespan [18].  
Similar to the insulin response pathway, TGF-β 
signaling comes through cell membrane receptors 
from upstream neuronal signals [51]. These neuronal 
signals function throughout the lifespan of C. elegans 
in order to regulate which developmental stage the 
nematode will transition into. In cases where envi-
ronmental signals do not necessitate entry into the 
dauer stage, the transition between juvenile and re-
productively mature nematodes occurs over a period 
of a few days, shortening overall lifespan significantly 
in comparison to dauer animals. One critical mod-
erator of reproductive maturity/capability is the ‘Egg 
Laying Deficient’ (EGL) family of proteins, which 
have many roles in C. elegans development. The egl-4 
member of the family (which encodes a cyclic 
GMP-dependent protein kinase) functions in con-
junction with the TGF-β pathway, with its mutation 
resulting in pro-dauer DAF-3/5 (Smads) activity and 
entry into dauer [51]. However, while egl-4 mutations, 
by indirectly inhibiting TGF-β, cause entry to dauer, 
the dauer formed is abnormal with development se-
verely altered. Along with this, the mutation in egl-4 
(and resultant TGF- β signaling) affects critical de-
velopmental processes such as neuronal signaling, 
body size and the ability to lay eggs [51]. In terms of 
its effect on dauer formation, the mutation of egl-4 
which causes deficiencies in neuronal signaling, links 
egl-4 mutation to the inhibition of TGF-β, since the Int. J. Biol. Sci. 2010, 6 
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TGF-β receptors are dependent on receiving these 
neuronal signals. This response indicates that active 
egl-4 could be critical to TGF-β signaling, and resul-
tantly, dauer entry [51].  In this respect, age-1/akt 
pathway mutations show similar phenotypic re-
sponses to egl-4 mutants, notably in increased size 
(possibly linking this to the LKB1/AMPK activated 
fat accumulation), which is a pre-dauer event. An 
interesting response to egl-4 mutations is that chemo-
sensory signaling disruption may be reversed by 
subsequent mutations in daf-3/5 (Smads) suggesting 
that they may work downstream of egl-4. This could 
implicate the Smads as feedback inhibitors of TGF-β 
signaling, similar to the actions of Smad 6/7 members 
in mammalian systems, in order to select for dauer 
entry [51]. 
An alternative TGF-β pathway, which functions 
through the type II receptor (DAF-4) and alternate 
downstream Smads (SMA-2, 3 and 4), appears to a 
lesser extent than the standard DAF-7/ DAF-1:DAF-4 
led pathway, to be involved in development such as 
body size determinacy [49]. These Smads, which have 
been suggested to form a heterotrimer complex, are 
activated by phosphorylation of a consensus sequence 
at the C terminal end of the protein. The C. elegans 
SMA-2 and 3 (apparent homologues of r-Smad 2 and 
3) are thought to complex individually or together 
with SMA-4 (a potential co-Smad, Smad-4 homolog) 
after phosphorylation. The complexes subsequently 
move into the nucleus in order to interact with tran-
scriptional co-factors [50]. While in all models of 
Smad activity, phosphorylation is critical, it is sug-
gested that in the C. elegans system, phosphorylation 
is more relevant to binding transcriptional co-factors 
than to nuclear translocation [50]. Mutations in either 
sma-2 or -3 lead to a shortened body size defect, which 
shows their role in normal body size development, 
and also possibly a necessity in pre-dauer accumula-
tion of fats.  
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Figure 5: TGF-β signaling in C. elegans. The TGF-β ligand (DAF-7) stimulates the type II receptor (DAF-4), which in turn, 
recruits and phosphorylates the type I receptor (DAF-1). DAF-1 phosphorylates (activates) downstream Smads (DAF-14), 
which complex with DAF-8 and enter the nucleus. In the nucleus, the DAF-8/-14 complex inhibits pro-dauer Smads 
(DAF-3/-5) and promotes development, rather than dauer formation. An alternate Smad based pathway involves het-
ero-trimer formation of a combination of SMA-2/-3 and 4. These trimers enter the nucleus, associate with transcriptional 
co-factors and regulate body size development of C. elegans. Int. J. Biol. Sci. 2010, 6 
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 The TGF-β pathway appears to repress dauer 
entry, in conjunction with its roles in growth and de-
velopment, but it has been suggested that it may only 
function this way at the L2d (pre-dauer)/Dauer state 
junction [49]. Since TGF-β (DAF-7) signaling is 
prevalent in many tissue types of C. elegans, including 
hypodermis (which is critical for regulation of body 
size), intestine and pharynx, it may be involved in the 
physiological preparation during transition into 
‘pre-dauer’ (L2d) larvae [49]. To further this, there is 
an alternate target of the TGF-β pathway which 
counteracts AKT activity rather than mirroring it. In 
the L2d stage, DAF-7 signaling has been shown to 
increase daf-18 (PTEN) expression [24]. Once DAF-18 
is active, the production of phosphatidylinositol-3, 4, 
5-trisphosphate, by AGE-1 (PI3K) is reversed and 
AKT phosphorylation is subsequently lowered. This 
is manifested as an increase in DAF-16 in the nucleus 
and the entry of C. elegans larvae into their dauer stage 
[24].  
Target of Rapamycin Kinases: Interactions 
with the Insulin Response Pathway and 
Regulation of Dauer Entry 
The Target of Rapamycin (TOR) kinases are 
highly conserved in multicellular organisms and are 
involved in numerous critical cell processes including 
protein synthesis, cell cycle regulation and auto-
phagy. In mammals, mTOR (mammalian target of 
rapamycin) regulates protein translation and the cell 
cycle, primarily by promoting protein synthesis [52]. 
The PI3K/Akt cascade, as part of the insulin response 
pathway activates mTOR through phosphorylation. 
The primary function of mTOR is to regulate transla-
tion by phosphorylating two key proteins, p70-S6 
protein kinase (P70S6K) and the eIF-4E binding pro-
tein (4E-BP). P70S6K is activated by mTOR whereas 
phosphorylation of 4EBP inhibits its binding to eIF4E. 
However, mTOR is also known to interact with PP2A 
which, in turn, helps to sustain protein synthesis by 
dephosphorylating protein synthesis inhibiting ma-
chinery [52].  
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Figure 6: Mammalian target of rapamycin (mTOR) activation pathway. Formation of the mTOR complexes (mTORC1 and 
C2) is dependent on regulation of the tuberin/hamartin (TSC1/2) complex. This is regulated by numerous kinases, which can 
inhibit (AKT) or activate the complex (GSK-3β and AMPK). Active TSC1/2, interacting with Rheb-GTP, inhibits mTOR 
complex formation, and subsequent downstream activities. mTOR activation is often based on nutrient availability. Int. J. Biol. Sci. 2010, 6 
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The action of mTOR in regulating the 4E-BP1 is 
well known. When eIF4E is bound to 4E-BP1 it is 
prevented from joining the translation initiation 
complex but upon phosphorylation by mTOR, 4E-BP1 
releases eIF4E which is then phosphorylated by 
p70S6K and can join the active initiation complex [52]. 
The eukaryotic elongation factor (eEF2) is also regu-
lated by mTOR. eEF2 is phosphorylated and inacti-
vated by eEF2 kinase (eEF2K) which is, in turn, 
phosphorylated and inactivated by p70S6K as a result 
of mTOR activity (Fig. 6). As a consequence of mTOR 
action, therefore, p70S6K is activated, eEF2K is inac-
tivated, and eEF2 is activated. This allows the elonga-
tion complex to form and support active protein 
translation. mTOR is also seen to promote the trans-
lation of calmodulin dependent kinase (CAMK) sub-
units and microtubule associated proteins (MAP2), 
both of which are involved in maintaining progres-
sion in the cell cycle  [52]. Under these conditions, 
calmodulin-dependent protein kinase (CAMK) acts 
upstream of ERK1, which in turn, acts upstream of 
p27, the cell cycle attenuator. CAMK phosphorylates 
and activates ERK, and ERK phosphorylates and in-
activates p27. The MAP2 protein is active in the G2 
phase of the cell cycle, stabilizing the microtubules by 
cross-linking them with themselves.  
Maintaining active TOR complexes through the 
TSC1/2 barrier: 
Two mTOR complexes are found in mammals, 
mTORC1 and C2, both with distinct and varied func-
tions. The mTORC1 complex combines mTOR and the 
‘regulatory associated protein of mTOR’ (Raptor), 
whereas in mTORC2, mTOR complexes with the ‘ra-
pamycin insensitive companion of mTOR’ (Rictor) 
and a stress activated protein kinase interacting pro-
tein (SIN). Both complex with a G-protein subunit 
(GβL) (Fig. 7) [52]. mTOR signaling essentially medi-
ates amino acid availability for protein synthesis. 
Under high amino acid availability, a Class III PI3K 
(Vsp34) is activated and through the recruitment of 
PIP3 and PDK, activates Akt, which then has two 
means of activating mTOR. Akt can phosphorylate 
either Pras 40 or the tuberin/hamartin (TSC1/2) com-
plex to prevent their inhibitory effects on mTOR (Fig. 
6) [52]. In this, albeit complicated, way, Akt activity 
maintains mTOR activity.   
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Figure 7: mTOR complex formation combines either Raptor (C1) or Rictor (C2). Inhibition of mTORC1 by FKBP38 can be 
reversed by direct interaction with Rheb-GTP. Both complexes have downstream targets to promote cell cycle progression 
and protein translation, but mTORC2 also has feedback activation of mTOR activation through AKT phosphorylation. Int. J. Biol. Sci. 2010, 6 
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Along with their AKT maintained activity, 
mTOR complexes also require protection from prolyl 
isomerases (which are indicated in protein folding), 
which bind to mTOR, preventing their phosphoryla-
tion capacity. FKBP38 binds and inhibits the mTORC1 
complex [53]. To counteract this, a Ras like GTPase, 
Rheb (Ras homolog enriched in brain), binds to GTP 
m a k i n g  i t  a n  e f f e c t o r  o f  FKBP38. When Rheb-GTP 
binds FKBP38, it is released from the mTORC1 com-
plex, thereby nullifying its effects (Fig. 7) [53]. The 
stimulation of mTOR activity by high amino acid lev-
els is reflected in a reduced level of FKBP38-mTOR 
interactions and subsequently increased 
Rheb-FKBP38 binding [53].   
At the TSC1/2 branch point, there are a number 
of kinases that can act, and while phosphorylation 
from Akt prevents the complex from inhibiting 
mTOR, phosphorylation at alternate sites can activate 
it.  Under energetically stressful conditions, AMPK 
signaling increases (due to high AMP) and along with 
glycogen synthase kinase beta (GSK-3β), can phos-
phorylate the TSC1/2 complex and lead to mTOR 
inhibition (Fig. 6) [52].   
As part of its actions in cell cycle regulation, 
mTOR maintains a novel interaction with the serum 
glucocorticoid regulated kinase (SGK). Acting on the 
p27 member of the ‘kinase inhibitor protein’ (KIP) 
family, which incidentally can also be phosphorylated 
directly by Akt, mTOR maintains the progression of 
the cell cycle (Fig. 9) [54]. The direct binding of p27 to 
E-type cyclin-CDK2 complexes prevents the cell cycle 
from progressing to the S phase. Phosphorylation of 
p27 by mTOR prevents p27 from entering the nucleus 
and it accumulates in the cytoplasm (Fig. 9) [54]. The 
mTORC1 complex also acts upstream of SGK-1 to 
phosphorylate it in the hydrophobic (H) motif, prior 
to SGK1 being phosphorylated by PDK1 and becom-
ing fully activated [54]. The mTOR complexes also act 
as H motif kinases to P70S6K (through mTORC1) and 
Akt (through mTORC2).  The mTOR/SGK interac-
tion not only maintains cell cycle progression but has 
important implications in the entry into the dauer 
stage for C. elegans, which are elaborated below. 
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Figure 8: The C. elegans pathway of mTOR production is dependent on insulin/IGF response. TOR homologs DAF-15 
(Raptor) and LET-363 (TOR) are regulated by DAF-16 (FoxO) transcription factors which are also responsible for entry into 
dauer. A. Shows high nutrient conditions, with insulin signaling, through active AGE-1(PI3K) and AKT phosphorylating 
DAF-16, impeding its entry into the nucleus and allowing transcription of the TOR genes. B. When phosphorylation of AKT 
is blocked by DAF-18 (PTEN), DAF-16 is able to enter the nucleus, and can inhibit the transcription of TOR genes. Int. J. Biol. Sci. 2010, 6 
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Figure 9: TOR interactions with SGK1 in both mammalian and C. elegans models. A. Phosphorylation of SGK1 by mTORC1 
and then PDK activates the kinase, before it acts upon p27. Phosphorylated p27 is unable to bind E-type Cyclin – CDK2 
complexes, which in turn allow progression into the S phase of the cell cycle. B. The C. elegans TORC2 complex phos-
phorylates SGK-1 which modifies DAF-16 to prevent entry into dauer, and increases lipid stores, possibly as a preparation 
for dauer. 
 
The activation or inhibition of mTOR also ap-
pears to have an effect on autophagy; the process of 
recycling cellular components and reducing the size 
of the cell. In periods of energetic deficit such as dur-
ing MRD, reduced mTOR activity and increased 
AMPK activity could lead to autophagy.   Oppositely, 
under conditions of increased amino acid availability, 
which correlate with elevated mTOR activity, auto-
phagy is suppressed [52].  The topic of autophagy 
will be further elaborated later in this review. 
The translational effects of mTOR are typically 
necessary to the progress of the cell cycle, but when an 
organism transitions into a hypometabolic state, it is 
important to shut down energetically expensive 
processes, such as protein synthesis. This typically 
leads to a suppression of insulin signaling (and other 
growth factor) pathways, leading to reduced Akt and 
mTOR activities. Such is the case in C. elegans as it 
enters the dauer stage of larval development. The 
dauer stage, which is triggered by stressful conditions 
(e.g. temperature rise, lack of oxygen, lack of food), is 
characterized by pre-accumulation of lipid stores, the 
suppression of the PI3K/Akt (Age-1/akt  in C. ele-
gans) pathway and the up-regulation of FoxO tran-
scription factor (Daf16 in C. elegans) activity.   
The anti-dauer activity of C. elegans TOR:  
In the C. elegans model, the TOR family is repre-
sented by two members, DAF-15 (a C. elegans ortholog 
of Raptor) and LET-363(TOR), which have been 
shown to play a role, by their suppression, in entry 
into the dauer stage [55]. The two TOR proteins asso-
ciate to function as one, with DAF-15 acting as a 
bridging protein between TOR and its targets. Sup-
pression of this complex results in enhanced fat stor-
age, possibly in preparation for the dauer period [55]. 
As in mammalian systems, TOR functions   in the 
AKT controlled insulin-response pathway in C. ele-
gans and its activation pattern mirrors that of the AKT 
family of kinases (AKT-1 and 2) (Fig. 8) [55]. Typi-Int. J. Biol. Sci. 2010, 6 
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cally, when nutrient levels are high, and reproductive 
growth is possible, the genes mediating reproduction 
and increased metabolism are activated by TOR 
which in turn is regulated by AKT. In this system, 
AKT inhibits DAF-16 through phosphorylation which 
prevents DAF-16 entering the nucleus and binding 
the regulatory region of daf-15, preventing its tran-
scription (Fig. 8). DAF-16 may also inhibit TOR 
through a series of currently unknown downstream 
transcription factors [55]. Thus, under limited nutrient 
conditions, associated with the preliminary conditions 
of dauer formation, AKT activity is minimized, lead-
ing to active DAF-16, and then decreased TOR 
(let-363/daf-15) activity. The DAF-16 downstream ef-
fectors are activated, while the inactivity of TOR leads 
to an accumulation of fat [55]. In the pre-dauer stage, 
fat accumulation in the intestinal and hypodermal 
cells takes place, providing an energy source 
throughout their anti-senescence period.  
The regulatory profile of TOR and DAF-16 is also 
affected by the PTEN phosphatase (DAF-18). It is 
suspected that DAF-18 and DAF-16 have compli-
mentary activities, with DAF-18 able to directly 
de-phosphorylate DAF-16, as well as prevent the up-
stream kinase, AKT, from becoming active. Indeed, 
DAF-18 is able to dephosphorylate PIP3, which if ac-
tive, would activate (phosphorylate) first PDK and 
then AKT (Fig. 6 and 8) [55].  In a similar manner, 
PP2A affects TOR activity by directly 
de-phosphorylating akt, preventing its downstream 
activity. This PP2A effect has been put forward as a 
mechanism to support DAF-16 entry into the nucleus 
and initiate the dauer response (Fig. 6) [56]. Hence a 
correlation between high phosphatase activity and 
low TOR activity could be predicted as a marker of 
entry into the dauer stage. 
The relationship between TOR and SGK (SGK-1 
in  C. elegans) in mammalian systems maintains cell 
cycle progression via inhibition of p27 [54], but in C. 
elegans a novel role of the TORC2 complex is seen that 
affects fat accumulation, a critical preparatory factor 
for prolonged dauer periods [57]. The C. elegans Rictor 
homolog, while not apparently necessary for early 
development, has a role in pre-dauer development, 
primarily as an effector of AK T, as part of the TORC2 
complex.  It is thought that TORC2 recruits SGK-1 to 
affect fat accumulation and body size [57]. Mutations 
in both C. elegans Rictor and sgk-1 showed the same 
phenotypic response of increased lipid stores and 
shortened body sizes, indicating their direct relation-
ship (Fig. 9) [57]. This indicates a novel role of SGK-1, 
which had previously been implicated in suppression 
of DAF-16 (via phosphorylation) as an anti-dauer re-
sponse.    
The relationship between TOR and AMPK: 
To conclude this section, a short discussion of 
AMPK effects is needed. As mentioned above, the 
inverse relationship between the activity of TOR and 
AMPK is critical for long term survival. AMPK is not 
critical to dauer entry, but its absence causes prema-
ture death in C. elegans as a result of a rapid con-
sumption of energy stores and consequent organ 
failure while in the dauer stage [58]. AMPK, identified 
in many systems as a critical metabolic regulator, 
maintains energetic homeostasis by regulating the 
consumption of stored lipid reserves during the dauer 
period [58]. Key to lipid consumption is regulation of 
the activity of adipose triglyceride lipase (ATGL, 
ATGL-1 in C. elegans), that is phosphorylated by 
AMPK at multiple sites [58].  AMPK activity is 
regulated in two ways; post-translationally and by 
translation of its catalytic subunit, AAK. The het-
ero-trimeric AMPK complex is dependent on AMP 
signaling, but can attain increased activity through 
phosphorylation. The serine/threonine kinase, LKB1 
(C. elegans PAR-4) in a complex with two cofactors, 
phosphorylates AMPK, likely at the α2 (AAK-2) sub-
unit to significantly increase its activity. In cases 
where AMPK catalytic subunit expression is sup-
pressed, primarily AAK-2, rapid lipid depletion is 
seen and the life span of these nematodes drops to 
about one-third of control values; this can be reversed 
with resumed AAK-2 production [58].  
The STAT Family: Regulation of Develop-
ment and Interactions with TGF-β to regulate 
C. elegans Lifespan     
The ‘Signal transducer and activators of tran-
scription’ (STAT) family of transcription factors are a 
highly conserved family of proteins involved in de-
velopmental signaling. The STAT pathway has par-
allels with the TGF-β pathway in that it is largely 
based on responses to growth-factors and cytokines, 
and is primarily involved in development.  The 
STAT transcription factors are also involved in host 
immunity, formation of blood cells and inflammation 
responses [59]. The mammalian STAT family contains 
seven members, with STAT-1 and STAT-3 being the 
prominent members [59]. STAT activation is a con-
served process and requires tyrosine phosphorylation 
(tyr 701), typically by the Janus kinase family (JAK), 
which allows nuclear translocation and subsequent 
transcription factor activity. STATs are also able to 
interact in a protein-protein fashion in order to en-
hance/suppress target protein activity.  
Regulating the transcription factors are numer-
ous inhibitors, which act on the STATs at different Int. J. Biol. Sci. 2010, 6 
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stages of their activity. They include the ‘suppressors 
of cytokine signaling’ family (SOCs), which prevent 
STAT phosphorylation by JAK by binding the recep-
tor site on the transcription factor, and the ‘protein 
inhibitors of activated STATs’ (PIAS), which bind 
phosphorylated STATs and prevent transcriptional 
activity (Fig. 10) [60]. These inhibitors, while acting on 
mainly on STATs, also have roles in apoptosis sup-
pression and cell cycle regulation. 
STATs in stress response and their interactions 
with known SREs: 
As part of their role in development, the STATs 
aid in determining the survival state of cells that have 
been exposed to ischemia (restricted blood flow, cut-
ting off oxygen and nutrient delivery and waste re-
moval from cells) and reperfusion (resumption of 
blood flow). Ischemia/reperfusion (I/R), a significant 
factor in the damage done during stroke or heart at-
tack, triggers divergent responses by members of the 
STAT family; specifically via STAT-1 and STAT-3 [61]. 
Interestingly, however, these two have contradictory 
responses, STAT-1 mediating apoptosis signaling 
whereas STAT-3 mediates protective responses. Fol-
lowing I/R insult, phosphorylation of STAT-1 by JAK 
or MAPKs leads to nuclear translocation, the 
up-regulation of pro-apoptotic genes such as Fas, 
Fas-L (the ‘death receptor’ and its ligand, respec-
tively) and Caspase-1, and the repression of 
anti-apoptotic proteins such as Bcl-2 and Bcl-xL (Fig. 
10) [61]. In keeping with a pro-apoptotic role, STAT-1 
also binds directly to the tumor suppressor protein, 
p53, which aids p53 binding to pro-apoptotic protein 
promoter sites. STAT-1 also binds the MDM2 pro-
moter, repressing its expression (Fig. 10) [60]. This 
repression enhances the stability and activity of p53, 
which may otherwise be bound and inactivated by 
MDM2 (see further discussion below in the p53 sec-
tion).  
 
STAT-1 STAT-3 STAT-2 STAT-7 STAT-4 STAT-5 STAT-6
JAK
P73
P53
SOCS
PIAS
MDM2
STAT-1
P
STAT-3
P
P53
Bcl-2 Fas-L Caspase Fas Bcl-xl SOCS
STAT-1
P
P53
MDM2
Nucleus
Development and 
host immunity
Apoptosis
= STAT-1 path
= STAT-3 Path
= Alt. STAT-1 activity
P53
 
Figure 10: Mammalian STAT signaling controls multiple developmental processes. Key members of the STAT transcription 
factors, STAT-1 and 3, also regulate apoptosis. STAT-1 transcriptionally up-regulates apoptosis signaling genes, as well as 
interacting with the P53 tumour suppressor. This interaction increases P53 activity. Active P53 may also inhibit STAT-3 
activation, which would prevent the downstream up-regulation of anti-apoptotic/anti-STAT-1 proteins. Int. J. Biol. Sci. 2010, 6 
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The pattern of positive regulation of STATs by 
p53 is not uniform, however, since active p53 pro-
motes the inhibition of STAT-3 (Fig. 10). STAT-3 may 
be classified as an oncogene due to its constitutive 
expression in numerous cancerous tissue types and its 
downstream transcriptional targets that inhibit 
apoptotic signaling or maintain cell cycle progression 
[62]. Although the mechanism is not clear, p53, possi-
bly by repressing JAK expression or increasing tyro-
sine phosphatase activity, prevents STAT-3 phos-
phorylation and subsequently affects its DNA binding 
capacity [62]. As a result, this may act as a 
pro-apoptotic signal, since STAT-3 is able to increase 
the expression of anti-apoptotic Bcl-2 and Bcl-xl, the 
same proteins that are repressed by active STAT-1 
(Fig. 10) [60]. Similarly, p53 affects the cyto-
kine-induced STAT5 as part of a pro-apoptotic 
mechanism [62]. In conjunction with P53/STAT-1 
interactions, PIAS-1 (the STAT-1 inhibitor) is also 
known to bind p73 (a member of the p53 tumor sup-
pressor family) and sumoylate it (Fig. 10). This pre-
vents critical downstream transcriptional effects on 
Bcl-2 family members and cell cycle regulators such as 
p21 [63]. 
In addition to I/R, hyperosmotic shock is an-
other stress that can trigger STAT responsive signals. 
Hyperosmotic stress (e.g. due to dehydration or hy-
persalinity) trigger the p38 MAPK, through its up-
stream activator MKK6, which in turn is able to regu-
late STAT activity. Under these conditions p38 MAPK 
phosphorylates the critical tyrosine residue on 
STAT-1, activating the transcription factor, while also 
phosphorylating the tyrosine phosphatase SHP2 [64]. 
This should inactivate the phosphatase (however this 
remains undetermined [64] which would otherwise 
act to repress STAT phosphorylation. 
Since stress activated protein kinases like p38 
MAPK can activate the STATs, a link between STAT 
activation and one of the major stress responsive 
pathways, the insulin/IGF pathway, may be ex-
pected. Hence, in a relatively recent discovery, it has 
been shown that the Insulin/IGF pathway, which 
typically signals via the PI3K/Akt cascade, also sig-
nals the JAK/STAT pathway. The SOCs STAT in-
hibitors are able to repress this via direct interaction at 
the insulin-like growth factor I receptor (IGF-IR), 
which may also affect the canonical insulin response 
pathways [65]. In addition, SOC production can be-
come part of a feedback inhibition loop, with STAT-3 
able to up-regulate their transcription [66].   
The role of STA-1 in development and dauer: 
Whereas in vertebrates, the STAT family of 
transcription factors are important in many biological 
processes such as cytokine signaling and host immu-
nity, in C. elegans they may also play an important 
regulatory role in the transition into the dauer stage. 
The STA-1 transcription factor, a STAT ortholog, 
regulates larval development parallel to and in con-
junction with TGF-β. Along with the DAF-16 and 
Smad (DAF-8/14) transcription factors, STATs are 
emerging as key regulatory switches through their 
actions in repressing dauer formation and promoting 
senescence.  
As in mammalian systems, STA-1 is regulated by 
tyrosine phosphorylation, which is required for entry 
of the transcription factor into the nucleus and DNA 
binding (Fig. 11). In C. elegans, sta-1 expression is seen 
in most of the same tissues as TGF-β (including intes-
tine, pharynx, and critically for development, muscle), 
once again indicating a parallel response [67]. Though 
STA-1 only holds a 22% amino acid homology to 
mammalian STATs, it maintains the conserved re-
gions that characterize tyrosine phosphorylation and 
transcriptional regulation. STAT phosphorylation in 
mammals is typically mediated by the JAK family, but 
although STA-1 is known to be phosphorylated, the 
kinase responsible has not yet been identified [67].  
While STA-1 responses could be characterized as 
anti-dauer (in the line of TGF-β), its expression is seen 
throughout the dauer period as well as prior to it. Its 
activity remains unchanged throughout the latency 
period and into subsequent developmental stages 
[67]. This would typically indicate a role less focussed 
on dauer determinacy than continuous development. 
However, the continuous activity profile is likely 
what allows STA-1 to act as a compensatory element 
in TGF-β signaling.  
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Figure 11: STA-1 Signaling in C. elegans. Standard STA-1 activity mirrors the TGF-β pathway, in terms of contribution to 
development, but there is an alternate mechanism in which STA-1 directly interacts with members of this path. In the 
absence of DAF-7, 4 or 14, STA-1 is able to directly contribute to TGF-β signaling through interactions with the DAF-1 
receptor or the downstream Smad, DAF-8. There is also a proposed feedback inhibition of dauer initiation through 
(pro-dauer) DAF-3 regulated transcription of sta-1. 
 
Like the TGF-β pathway, STA-1 signaling is 
heavily influenced by neuronal signaling. The absence 
of STA-1 at raised temperatures (which would possi-
bly be conducive to dauer signaling conditions) re-
sults in ~30% higher rates of dauer entry [67]. Thus, 
like TGF-β, the C. elegans S T A T  h a s  b o t h  d e v e l o p -
mental and dauer responsive roles which it performs 
in conjunction with TGF-β. STA-1 can act to repress 
dauer through two paths; one compensatory and one 
feedback [67]. In the first mechanism, STA-1 itself can 
activate anti-dauer signaling through interactions 
with the type I receptor (DAF-1) and downstream 
Smad (DAF-8) (Fig. 11) [67]. These interactions indi-
cate a break from the canonical TGF-β signaling, and 
possibly indicate a compensatory activation in the 
absence of DAF-7(TGF-β ligand), DAF-4(type II re-
ceptor) or DAF-14 (Smad). The secondary mechanism 
involves up-regulation (via increased transcription) of 
sta-1, and then activity through the first mechanism. 
The  sta-1 sequence contains Smad binding regions, 
which in a mechanism of feedback inhibition, allows 
interaction with the pro-dauer Smad, DAF-3 (Fig. 11) 
[67].   
Programs of Cell Death or Degeneration in 
Response to Stress: Apoptosis or Autophagy?   
Apoptosis: 
Apoptosis or programmed cell death is a process 
by which cells are destroyed in a regulated manner; 
often this occurs as a response to extreme stress but it 
is also an integral part of programs of development 
and senescence. Apoptosis is characterized by chro-
matin damage and resultant DNA cutting [68]. The 
primary mediators of apoptosis are cysteine proteases 
of the ‘caspase’ family that are targeted directly or 
indirectly (i.e. through second messengers or 
pro-apoptotic proteins) and which, in turn, trigger a 
host of proteins such as endoribonucleases and pro-Int. J. Biol. Sci. 2010, 6 
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teases.  
The control of apoptosis through mitochondrial 
integrity: 
Apoptosis can be signaled by a number of dif-
ferent stress conditions such as DNA damage, oxy-
gen/energy debt or starvation, but the response 
pathway remains fairly conserved, with the mito-
chondria being the key to its initiation. Regulating the 
mitochondrial response is the B-cell lymphoma 2 
(Bcl-2) family of proteins, and within this group, spe-
cifically, the BH3-only members of the family [69].  
The BH3 (Bcl-2 Homology 3) domain and its com-
plementary binding cleft are critical to the activity of 
these proteins, with the majority of their pro-
tein-protein interactions occurring at these sites. The 
Bcl-2 family contains both pro (Bax, Bak, Bim) and 
anti (Bcl-2, Bcl-xl, Bcl-3) apoptotic members, which 
through the BH3 domain are able to interact with each 
other [69]. These bindings either result in the stimula-
tion of apoptosis (i.e. the homo-dimerization of pro 
apoptotic members) or its inhibition (i.e. the het-
ero-dimerization of a pro- and anti-apoptotic mem-
ber). Pro-apoptotic members of the family, primarily 
Bax or Bak, translocate to the mitochondrial mem-
brane when activated, and stimulate outer mitochon-
drial membrane permeability (OMMP). This allows 
the release of proteins/secondary messengers from 
the inter-membrane space (IMS) into the cytosol; of 
particular importance is cytochromes C release. Sub-
sequently, caspases are activated through cleavage, 
dimerization, and auto-proteolysis reactions, and go 
on to trigger downstream cell death proteins such as 
DNAases, proteases and ‘inhibitor of apoptosis’ (IAP) 
antagonizers [69]. Hence the idea of mitochondrial 
membrane maintenance as the key to apoptotic regu-
lation is formed.    
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Figure 12: Apoptotic signaling in C. elegans (A) and mammalian (B) models. The anti-apoptotic Bcl-2 family members (CED-9, 
Bcl-2 and Bcl-xl) bind pro-apoptotic proteins attempting to locate to the outer mitochondrial membrane (OMM), neu-
tralizing their activity. At the OMM, pro-apoptotic BH3 containing proteins will form a pore (OMMP) which allows mito-
chondrial proteins and second messengers to enter the cytoplasm, signaling downstream caspase activity (though it is 
unknown if cytochrome C release is a factor in C. elegans  apoptosis). In both models, apoptosis and autophagy (via 
Bax/DRP-1 and Beclin-1) may be inhibited by Bcl-2/CED-9 binding. In the mammalian model, this can be reversed through 
the phosphorylation of Bcl-2 by JNK. Int. J. Biol. Sci. 2010, 6 
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The physical dynamics of the mitochondrial 
membrane are either stabilized through fusion events 
where mitochondria form interconnections, or desta-
bilized through mitochondrial fragmentation (or ‘fis-
sion’), which destroys the integrity of the membrane 
and leads to apoptotic signaling. The proposed 
Bax/Bak interaction which occurs at the OMM is 
suspected to disrupt the lipid bilayer, creating an 
OMM pore [69]. To regulate the formation of these 
pores, the Bcl-2 and Bcl-xl anti-apoptotic members of 
the Bcl-2 family form hetero-dimers through a pro-
tein-protein interaction, preventing the Bax/Bak 
homo-dimer interaction, nullifying their OMM pore 
formation capacity (Fig. 12). By contrast, the tumor 
suppressor p53 is shown to promote apoptosis pri-
marily through transcriptional activation of 
pro-apoptotic genes (PUMA, Noxa, Bax), but is also 
speculated to bind directly to the Bax/Bak oligomer 
and activate it. This correlates with role of p53 in 
apoptosis signaling, but is a novel, non transcrip-
tion-factor mechanism [69]. 
While we tend to focus on the interactions of the 
Bcl-2 family as a means of apoptosis suppression, the 
interactions function both ways, with a pro-survival 
signal equally likely to provoke an inhibitory re-
sponse from the pro-apoptotic members; possibly 
overwhelming the balance and eventually triggering 
apoptosis [69].   
The pathways of programmed cellular death in 
C. elegans: 
C. elegans have three major cell death pathways; 
apoptotic, autophagic and necrotic. The pathway 
triggered is dependent on the stress stimulus. Apop-
tosis signaling is largely characterized by DNA dam-
age and fragmentation of the chromatin, which trig-
gers the ‘C. elegans p53 like’ (CEP-1) transcription 
factor and EGL-1 (C. elegans ‘BH3-domain-death ac-
tivator’ homolog) responses [70]. Apoptosis in C. ele-
gans can occur in two phases. First, it is seen as part of 
the developmental process occurring at the embryonic 
stage and in the L2 larvae; resulting in the removal of 
muscular, hypodermal and neuronal cells as well as a 
large proportion of oocytes (reproductive/egg cells) 
from mature gonads [70]. Secondly, apoptosis may 
occur when induced by genotoxic stress, seen in the 
germline cells of hermaphrodites. Necrosis only oc-
curs under prolonged periods of cellular stress [70]. 
Acidification of the cell is the primary cause of ne-
crotic cell death.   Signaled by excess Ca2+ release, as a 
result of modification and degeneration of the calcium 
channels/exchangers, cellular calpains (which recruit 
ROS’s to the lysosomal membrane) trigger lysosomal 
rupturing [69]. With the physical degradation of the 
lysosome, cellular pH drops as H+-ATPases are dam-
aged, and the release of cathepsins (proteases) which 
are activated by the lowered pH cause the destruction 
of cellular components [70].  
Apoptosis in C. elegans: 
Apoptosis signaling in C. elegans, as in mam-
malian systems, can be initiated by the p53 tumor 
suppressor, CEP-1. CEP-1 transcriptionally 
up-regulates production of the ‘egg laying abnormal’ 
(EGL-1) protein [70]. EGL-1, like the BCL2 family of 
proteins, contains a BH3-only-domain, and when ac-
tivated, is thought to locate to the mitochondrial sur-
face, possibly in response to the presence of 
CED-9/CED-4 complexes. CED-9 and CED-4 are C. 
elegans homologs of Bcl2 and ‘apoptotic protease ac-
tivating factor 1’ (APAF1), and are anti- and 
pro-apoptotic, respectively.  Once at the mitochon-
drial membrane, EGL-1 causes membrane opening, 
and subsequent release of apoptosis signaling com-
ponents (Fig. 12) [70]. This may mirror the BH3-only 
protein (Bax/Bak) activity in mammals, which causes 
the formation of the OMMP. CED-4, in a sense, acting 
like caspase 8 in the mammalian caspase cascade, ac-
tivates the downstream C. elegans caspase (3/9) ho-
molog, CED-3. CED-3 starts as monomeric subunits 
which require dimerization and auto-proteolysis, and 
when functional acts as the ‘executioner kinase’, trig-
gering major cell destruction events such as protease 
activity [71]. Dimerization is mediated by CED-4, and 
is followed by auto-proteolysis which creates the 
functional subunits (large and small). Interestingly, in 
C. elegans (and mammalian models only), there is a 
protein which mimics the small subunit of CED-3, 
preventing functional caspase activity by binding the 
CED-3 monomer. While this may inhibit CED-3 ac-
tivity to a degree, its action can be overwritten by the 
induction of dimerization (of functional units) by 
CED-4 [71]. This level of control could be used to 
regulate non-specific apoptosis events which could 
harm larval development.  Concurrent with the 
CED4/3 pathway of apoptosis initiation, a series of 
CEDs including 7, 1, 6 and the cytoskeletal modifier, 
CED-10, modify the structure of a neighbouring cell in 
order to ‘engulf’ the apoptosed cell, for eventual 
degradation [70]. 
Mitochondrial fission, leading to fragmentation, 
is thought to be the major event in apoptosis signal-
ing, with the integrity of the outer membrane suscep-
tible to pro-apoptotic factors. This indicates that the 
activity of the BCL2 homolog, CED-9, is critical in 
maintaining mitochondrial structure. As in the 
mammalian system, pores formed in the outer mem-
brane are a result of binding by pro-apoptotic Int. J. Biol. Sci. 2010, 6 
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BH3-only proteins. The BH3 domains are also critical 
in the inhibition of these pro-apoptotic proteins, with 
BCL-2 able to bind Bax, and similarly a suspected 
CED-9: DRP-1 interaction in C. elegans [72]. DRP-1, the 
‘death associated protein kinase’ related protein 
kinase, is a serine/threonine kinase in C. elegans, and 
its over-expression is known to cause mitochondrial 
fission, which can lead to the release of important 
pathway signaling molecules such as cytochrome C, 
which is seen to trigger caspase activity in mammal-
ian systems, and ROSs. Conversely, over-expression 
of the CED-9 protein causes mitochondrial fusion [72]. 
The fusion event may be suppressed by up-regulation 
of DRP-1, which further indicates that binding of 
BH3-only proteins in their BH3 domain inactivates 
them, possibly resulting in a regulatory system of 
mitochondrial fission/fusion dependent on the rela-
tive activity levels of CED-9 and DRP-1 (Fig. 12) [72]. 
Whether this is important in apoptosis/caspase sig-
naling or not remains a contentious issue [73, 74].   
As mentioned above, the importance of the 
CED-9/DRP-1 interaction in regulating mitochondrial 
responsive apoptosis is in debate, but there appears to 
be a non mitochondrial role for DRP-1 in apoptosis 
signaling. The fission-1 (FIS-1) homolog, fis-2, in its 
standard role recruits DRP-1 to the mitochondrial 
membrane, promoting alteration of the outer mem-
brane and the potential signaling of downstream 
caspases CED-3 and 4. However, in knockouts ex-
periments of ced-3 and 4 where increase in the total 
number of viable cells indicated their roles in apop-
tosis, additional mutations in drp-1 and fis-2 further 
increased  the numbers of cells which survived. This 
indicates that these proteins associated with mito-
chondrial fission have (slight) apoptotic activity in-
dependent of the downstream caspases (CED-3/4) 
that fission would signal [73]. To further this, the 
non-mitochondrial fission role of DRP-1 appears to 
also require cleavage from CED-3 [73]. Thus, while it 
appears that as in mammalian systems, the majority 
of apoptosis responses arise from mitochondrial fis-
sion and caspase signaling, there may be alternate 
routes for the apoptosis machinery to initiate cell 
death.  
Autophagy: 
An alternative to complete cell death that is an 
option under some metabolic stress conditions is the 
relatively recently discovered process called auto-
phagy. Autophagy is the process whereby cells effec-
tively “down-size” themselves by degrading portions 
of their organelles and cytosolic components, recy-
cling them to obtain precursors and energy, and 
minimizing cell volume, in an attempt to prolong vi-
ability under stressful conditions. There are multiple 
forms of autophagy, the most prominent being 
‘macro-autophagy’. This follows the conserved model 
of autophagosome formation from free membrane. 
The autophagosomes section large portions of the 
cytoplasm and transport them to the lysosomes, 
where after a fusion event between lysosome and 
autophagosome, the contents are transferred [70]. 
While macro-autophagy is the main form, alternate 
forms of autophagy include chaperone mediated 
autophagy (CMA) in which cytosolic proteins are 
guided into the lysosomes by chaperone proteins, and 
micro-autophagy which involves direct lysosomal 
membrane invagination, cytoplasmic sectioning and 
subsequent degradation [70]. The common theme in 
autophagy is the engulfing of cytoplasmic fractions 
followed by their degradation.  
Macro-autophagy involves the multi-step for-
mation of autophagosomes which grow to encase a 
section of cytosol (that may also include organelles) 
and then fuse to lysosomes. The fused structure, 
known as an autophagolysosome, carries out the 
degradation of its contents w i t h  h y d r o l a s e s  [ 6 8 ] .  
Formation of the autophagosome requires coordi-
nated actions of multiple autophagy proteins, the 
Atgs, which are largely involved in complexing in 
order to bind and elongate the autophagosomal 
membrane (Fig. 13). The process begins by binding 
‘free cellular membrane’ to the initiating Beclin 1 
(Atg6) complex. Next, Atg proteins 5 and 12 begin a 
crucial conjugation mechanism mediated by Atg7 and 
10. Atg16 binds to the Atg12-Atg5 complex, which 
localize at the isolated membrane and initiate the 
elongation of the pre-autophagosomal membrane 
(Fig. 13) [68]. This process is extremely rapid, with the 
Atg12-Atg5 complex formed immediately after indi-
vidual Atg protein synthesis. The next stage, comple-
tion of the autophagosome, is mediated by Atg8 
(LC3), a microtubule associated protein. Atg8 is 
cleaved (Atg8c) and activated by Atg4 and is then 
conjugated to phosphatidyl-ethanolamine (PE) which 
then binds to the membrane and completes its forma-
tion (Fig. 13) [68]. Once formed, the autophagosome 
fuses with a lysosome, and its contents are degraded 
by hydrolases (Fig. 13) [68]. The target cell remains 
‘minimized’ until the stress has abated, after which, it 
can begin restructuring.  
Inducing autophagy by caloric restriction and 
tumor profiling: 
One of the key initiating conditions of autophagy 
is starvation. When faced with prolonged caloric re-
striction, autophagy is triggered to recover precursor 
molecules, limiting the energetic expense of resynthe-Int. J. Biol. Sci. 2010, 6 
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sis.    Along this line, another critical role of autophagy 
would be in the removal of nonessential proteins so 
that their amino acids can be recycled to meet synthe-
sis demands for essential proteins. Under normal ca-
loric intake, autophagy is naturally inhibited with the 
pro-survival Bcl-2 complexed with the autophagy 
initiator Beclin-1 [75].  Similar to its pro-survival role 
in binding pro-apoptotic proteins, Bcl-2 is suggested 
to bind Beclin- 1 at its BH3 domain. The dissociation 
of this complex, in order to induce autophagy, is me-
diated by mitogen activated protein kinases (MAPKs) 
and JNK (Fig. 12). By phosphorylating Bcl-2 at three 
sites within the critical ‘non-structured loop’ its 
physical conformation is altered, preventing it from 
binding to Beclin-1 [75]. This regulatory mechanism 
poses an interesting compromise between autophagy 
and apoptosis, with Bcl-2 binding both the 
pro-autophagy Beclin-1 and the pro-apoptosis Bax. 
With JNK being activated by starvation, the selection 
of autophagy or apoptosis is based upon duration of 
the exposure.  For example, HeLa cells subjected to 
short periods (up to 4 hours) of nutrient deprivation 
showed dissociation of the Bcl-2/Beclin-1 complex, 
indicating an early onset stimulation of autophagy. 
However, after 16 hours, and approaching maximal 
levels of Bcl-2 phosphorylation, Bcl-2/Bax complex 
dissociation along with Caspase 3 activation occurred, 
indicating apoptotic signaling [76].   
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Figure 13: Formation of the autophagosome, and subsequently, the autophagolysosome. Formation begins with the binding 
of isolated membrane by the Beclin-1 complex. This recruits further Atg proteins to the membrane, via nucleation, and 
initiates the elongation of the membrane by the Atg 12/5/16L complex. The cleaved Atg8 (LC3)/Phosphatidyl ethanolamine 
(PE) complex finalizes the formation of the autophagosome. Binding to and incorporation of the lysosome creates the 
autophagolysosome which is then able to degrade/recycle its contents through hydrolase activities. 
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The control of the Bcl-2 family by its own mem-
bers, in order to form active homo-dimers or inactive 
hetero-dimers, is not the only level of control on these 
proteins. Controls by JNK and p53 directly on indi-
vidual members, or complexes, function to effect a 
selection between autophagy and apoptosis. Like p53, 
the tumor suppressor p14 (ARF) is able to exert both 
p53 dependent (primarily through its inhibition of 
MDM2) and independent activities to determine the 
survival condition of the cell [77]. Beclin-1, as men-
tioned previously, is able to interact with the Bcl-2 
family members through its own BH3 domain (inter-
acting with the BH3 binding groove of the 
BH3-only-protein members). In a cell survival 
mechanism, both anti-apoptosis Bcl-2 and Bcl-xl can 
complex with Beclin-1, and inactivate autophagy [77]. 
Despite its positive interactions with the 
pro-apoptotic p53, ARF induces autophagy (as a 
function of its tumor suppressor capacity) by binding 
Bcl-xl, allowing isolated Beclin-1 to initiate auto-
phagy. When active, ARF localizes to the mitochon-
dria, where it is able to interact with Bcl-xl proteins at 
the outer membrane.  The physical complex between 
ARF and Bcl-xl can both sequester free Bcl-xl and un-
bind Beclin-1-bound Bcl-xl; this results in large in-
creases in autophagy [77]. Throughout, p53 maintains 
its role as an autophagy suppressor, by strongly re-
pressing the transcription of ARF. However, this re-
pression is largely seen in unstressed cells, suggesting 
that p53 regulates ARF in order to prevent unwanted 
autophagy [77].   
In the case of tumor suppression, both auto-
phagy and apoptosis are largely able to facilitate the 
process and, hence, the ability of p53 to also stimulate 
autophagy does not come as a surprise. While the 
cytoplasmic form (i.e. inactive for transcriptional 
regulation) inhibits autophagy via direct protein in-
teraction, its transcriptional activities have been seen 
to up-regulate both PTEN and TSC2, which lead to the 
inactivation of mTOR, a potent autophagy inhibitor. 
Specific to autophagy, active p53 also increases the 
transcription of ‘damage regulated autophagy 
modulator’ DRAM, which encodes a lysosomal pro-
tein that induces autophagy [78]. 
The relationship of mTOR and Beclin-1 in de-
termining the state of autophagy: 
To return to one of the aforementioned points, 
one of the major regulators of autophagy is upstream 
inhibition by the mTOR kinase.  This kinase which is 
responsible for maintaining protein synthesis and cell 
cycle progression is linked with pro-survival activity, 
and acts in competition with Beclin-1 to inhibit auto-
phagosome formation. Beclin 1(Vps 30) forms a class 
III PI3K complex, along with a tumor suppressor 
UVRAG and Vps34, which regulates the formation 
and nucleation of the autophagosome. Interestingly, 
both Beclin-1 and mTOR compete for Vps34 (Fig. 14). 
Signaled by high amino acid availability, Vps34 trig-
gers the activity of mTORC1, which can affect another 
critical initiator of autophagy, the Atg1 kinase (Atg1k) 
complex [79]. By hyper-phosphorylating Atg13, 
mTOR is able to prevent the complexing of Atg13 and 
Atg1, which is a critical step in the formation of the 
Atg1k complex [79]. Subsequently, the auto-
phagosome cannot be formed (Fig. 14). Beclin-1, 
which contains a conserved binding site for Vps34, 
can have its interaction broken by Bcl-2 family mem-
ber binding, in order to prevent autophagy (Fig. 13). 
Thus, the initiation of autophagy is, to a significant 
degree, dependent on which protein Vps34 complexes 
with. In nutrient rich conditions mTOR is likely to 
preferentially complex with it, and along with Bcl-2 
proteins, represses high levels of autophagy that 
would be detrimental to the cell. Conversely, under 
low nutrient conditions, it is likely that Vps34 pref-
erentially binds free Beclin-1, in order to maintain 
energetic homeostasis.   
Basal and induced autophagy in C. elegans de-
velopment: 
In C. elegans, the transition into the dauer stage is 
mediated by a number of critical changes which are 
imposed to allow survival, mainly without food. In 
the L2 larval stage, prior to dauer entry, autophagy 
proteins accumulate, and subsequently auto-
phagosomal bodies are formed [80]. Indeed, the initial 
s t e p  o f  a u t o p h a g y ,  m e d i a t e d  b y  B E C - 1  ( A t g 6 ,  H o -
molog of Beclin-1) is crucial to correct dauer forma-
tion. In the absence of bec-1, abnormal dauer forma-
tion results, often resulting in the premature death of 
the larvae [81]. Whilst BEC-1 appears to be the critical 
member in C. elegans dauer formation, deletions of 
autophagy proteins involved in complex formation 
(Atg1, 7 or 8) also resulted in abnormal dauers, but 
not to the extent seen when bec-1 was absent [81].  
Autophagy, in C. elegans, like apoptosis maintains a 
basal level of activity acting as a cellular quality con-
trol mechanism; this prevents the accumulation of 
protein aggregates and damaged organelles as well as 
mediating developmental transitions [82]. This role of 
cellular protection is in contrast to the levels of ex-
pression during energetic stress, which turns auto-
phagy from cellular protector to cellular recycler. In 
the case of the dauer stage, ATG genes are not crucial 
to entry, but their absence causes abnormalities that 
may prevent dauer transition, and even survival of 
the dauer stage [82]. Int. J. Biol. Sci. 2010, 6 
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Figure 14: Regulation of autophagy by mTOR and Beclin-1. Both compete for Vsp34, with Beclin-1 requiring it for its 
complex formation, and mTOR requiring it for its Rheb-GTP based activation. While Beclin-1 promotes autophagy, mTOR 
blocks autophagosome formation via Atg-1 kinase inhibition, by phosphorylating Atg13. 
 
To a degree, regulation of autophagy in C. ele-
gans and mammalian systems mirrors each other, as is 
also seen for their mechanisms of apoptosis regula-
tion. The link between TOR and autophagy appears to 
be intact, if activation patterns at the entry of dauer 
are compared. The link between autophagy initiation 
and mTOR suppression at the L2 stage, suggests that 
like in the mammal system, TOR suppression allows 
autophagy. Experimental evidence shows mutations 
in C. elegans TOR cause significant lifespan increase, 
lipid accumulation as well as altering nutrient ab-
sorption to create a caloric restriction profile. Caloric 
restriction, and the resulting slow down of metabolic 
processes, has been strongly linked to lifespan exten-
sion, and is an initiator of autophagy [70].  
The interaction between Beclin-1 and 
pro-survival Bcl-2, used to inhibit autophagy, is con-
served in the nematode model, with BEC-1/CED-9 
protein interactions disrupting the formation of the 
Beclin-1 initiation complex (Fig. 12). With Bec-1 
bound, it is not able to bind the C. elegans Vps34 ho-
molog [82].  Another mechanism also seems to occur 
where EGL depletion, along with the induction of 
starvation, indirectly induces autophagy [82]. Specu-
latively, this could indicate a mammalian-like 
Bax-Bcl-2-Beclin-1 compromise in C. elegans where 
under starvation conditions, CED-9 may bind 
pro-apoptotic EGL-1, leaving BEC-1 unbound. Inter-
estingly in C. elegans, the key autophagy complex 
protein, ATG5, may be proteolytically activated to 
translocate to the mitochondrial membrane, trigger-
ing cytochrome C release and resulting caspase activ-
ity [82], indicating once again, the high degree of 
cross-activation between autophagy and apoptosis 
signaling.  
Tumor Suppressor p53: Regulation of Apop-
tosis and Lifespan of C. elegans 
The tumor suppressor p53 is a stress activated 
transcription factor that regulates a number of down-Int. J. Biol. Sci. 2010, 6 
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stream targets involved with cell cycle control and 
apoptosis. Its activity, which requires it to be uncom-
plexed from the mouse double minute 2 (MDM2) 
protein, is triggered primarily by DNA damage sig-
naling [83]. The MDM2-p53 complex is broken by a 
number of post-translational modifications to both 
proteins that stabilize p53. Alternatively, if p53 re-
mains bound to MDM2, it is a target for ubiquitin 
ligase and subjected to proteasome-mediated degra-
dation. The primary means of isolating p53 from its 
complex with MDM2 appears to be phosphorylation, 
but it has over 24 sites for posttranslational modifica-
tion by mechanisms including phosphorylation, ace-
tylation, sumoylation, methylation and ubiquitination 
[83]. To this end, both the p53 target protein and 
MDM2 may be post-translationally modified, in order 
to break the complex (Fig. 15). The ‘mutated in 
ataxia-telangiectasia’ (ATM) kinase (possibly regu-
lated in part by Akt), responds to double-stranded 
DNA breaks and phosphorylates p53 on multiple 
serine residues, but p53 may also be phosphorylated 
by major stress response kinases such as p38 MAPK 
and JNK, as well as cell cycle checkpoint (CHK) 
kinases.  A further stabilization mechanism of p53 
occurs with the phosphorylation of its ubiquitination 
sites, releasing it from MDM2 and further, preventing 
its degradation. This can be seen with DNA damage 
induced JNK activity (Fig. 15) [83]. The p53 
C-terminus is the key regulatory region for its activity, 
with post-translational modification in this area 
helping to increase the DNA binding transcriptional 
activity of p53 [83]. 
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Figure 15: Activation of the p53 transcription factor begins with stress signaling (primarily DNA Damage). This triggers 
post-translational modification of the (inactive) p53-MDM2 complex, releasing and activating p53. P53 triggers death by 
halting the cell cycle, through p21, and triggering the caspase cascade, through Caspase 8. 
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Co-factor binding is also known to increase p53 
transcriptional activity. Phosphorylation of critical 
sites on the transcription factor can lead to the re-
cruitment of cofactors such as p300, CBP and P/CAF, 
which in turn promote acetylation of the p53 
C-terminus. This is a protective mechanism which 
prevents p53 ubiquitination, stabilizing the protein 
[83]. In cases of hypoxia, HIF1- and α p53 compete for 
the binding of p300 as a stabilizing co-factor, despite 
having opposite roles under hypoxic conditions. 
Whereas hypoxia causes the up-regulation of both of 
these transcription factors, they have roles in cell sur-
vival versus apoptosis signaling, respectively [84]. It 
has also been suggested that along with the competi-
tion to bind p300, the release of MDM2 from p53, can 
then cause the degradation (via ubiquitination) of 
HIF-1α [84]. 
 
The role of p53 in programmed cellular death: 
The role of p53 signaling has frequently been 
associated with programmed cellular death, via con-
trol of the caspase cascade (through Caspase 8), but 
also includes regulation of the cell cycle. This role, 
however, can be used for different results, with long 
term attenuation of the cell cycle used to signal 
apoptosis, and short term attenuation to correct mis-
takes occurring during the cell cycle and provide re-
covery from stress conditions. The cell cycle regula-
tory activity of p53 comes at the critical G1/S phase, 
prior to G2 and mitosis. When stable (most often as a 
result of phosphorylation via ATM kinase), p53 acts to 
up-regulate p21, which then binds to the cy-
clinE-CDK2 complex (Fig. 15). This binding prevents 
downstream phosphorylation, and entry into the S 
phase, halting the cell cycle [83]. 
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Figure 16: The protein-protein interaction between P53 and STAT1-p induces apoptosis and suppresses STAT3 protective 
mechanisms. STAT1-p inhibits transcription of anti-apoptosis BCL genes and enhances apoptosis signaling by p53 through 
binding. 
 
 
 Int. J. Biol. Sci. 2010, 6 
 
 
http://www.biolsci.org 
39
The STAT family of transcription factors has 
roles in both cell death and survival but in an interac-
tion with p53, they show a forcible move to apoptosis 
(Fig. 16). STAT1, when activated by phosphorylation, 
inhibits transcription of the anti-apoptosis BCL-2 
family genes whereas p53 itself, when signaled into 
action by DNA damage, can activate downstream 
cysteine proteases, specifically, Caspase 8. This enters 
the mitochondria, triggering cytochrome C release, 
which triggers an apoptosis signaling cascade 
through Caspase 9 [62].  STAT-1 acts in conjunction 
with p53, when phosphorylated by p38 MAPK or 
Janus kinase (JAK), in a novel protein-protein interac-
tion and the combined activity of p-STAT-1 and p53 is 
more efficient in apoptosis signaling than their inde-
pendent activities [62]. Conversely, STAT-3, which 
acts to protect against apoptosis under ische-
mia/reperfusion conditions, is inhibited (upstream) 
by p53 (Fig. 16) [62].  
The association of p53 with apoptosis has long 
been known, but it has recently become apparent that 
p53 is also involved in autophagy control. In mam-
mals, the p53 family consists of three homologous 
transcription factors; p53, p63 and p73 [85]. Whereas 
p53 is known to promote apoptosis (via caspase cas-
cades), p73 has a novel interaction with autophagy 
genes (Atg5 and 7). The mTOR protein kinase, which 
is a critical kinase in many stress response models, is a 
positive regulator of p53 (via phosphorylation activ-
ity), but a negative regulator of p73. Acting upstream 
of p73, mTOR inactivates the transcription factor, 
which in turn is unable to increase the transcription of 
autophagy proteins. As a result, loss of p73 function 
caused necrosis in some tissues [85]. Possibly in a 
negative feedback response, p53, via the recruitment 
of AMPK (likely acting on the TSC1/2 complex), has 
been shown to inactivate mTOR (Fig. 17).   
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Figure 17: P53, via recruitment of AMPK, regulates mTOR which in turn, is unable to inhibit the p53 family member, p73. P73 
is known to up-regulate transcription of autophagy genes. 
 
The DNA damage responsive Cep-1 in C. elegans: 
There appears to be only a single member of the 
p53 family represented in C. elegans, encoded by the 
cep-1 gene. However, with the importance of regulat-
ing autophagy during the dauer phase of life, CEP-1 is 
an important target for study. As in mammals, CEP-1 
is a tumor suppressor signaled by DNA damage and 
participates in apoptosis signaling. Specifically, CEP-1 
is triggered by ionizing radiation (IR)-induced DNA 
damage, and typically cep-1 deletions have only been 
seen to be lethal in the embryonic stage [86]. This 
likely represents the necessity of CEP-1 mediated 
apoptosis that is predominantly for development and 
houekeeping. The relationship between CEP-1 activ-
ity and cellular survival appears to follow the mam-
malian system, with a lack of CEP-1 making the 
nematode unable to assess DNA damage which 
causes substantial cellular damage. On the other 
hand, a forced over-expression of cep-1 can increase 
caspase activity, leading to apoptosis [87]. Ectopic 
apoptosis in the somatic tissue of C. elegans is not dealt 
with well, and often ends in death of the organism. 
CEP-1, which with excess stress signaling can trigger 
egg laying defective (EGL-1) protein mediated apop-Int. J. Biol. Sci. 2010, 6 
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tosis, is also able to interact directly with the CED (C. 
elegans caspase orthologs) family of proteins [87]. Ac-
tive CEP-1 up-regulates the transcription of a number 
of pro-apoptotic genes, particularly ced-13 and egl-1. 
CED-13 and EGL-1 act to bind anti-apoptotic (BCL2 
homolog) CED-9 protein, preventing its activity (Fig. 
18) [88]. Interestingly, though, another interesting 
point is the ability of CEP-1 to induce apoptosis in the 
absence of typical apoptotic machinery (CED3/4), 
suggesting that while CEP-1 may act upstream of the 
CEDs, it is not essential [86]. While in the mammalian 
system, a clear regulating protein (MDM2) has been 
established as controlling P53, a similar model in C. 
elegans is only suspected at this point. The 
Skp1/cullin/F-box (SCF) E3 ubiquitin ligase 
(SCFFSN-1) has been identified as a potential CEP-1 
regulator. In germline cells it has been discovered that 
the SCFFSN-1 inhibits CEP-1, but through an unknown 
intermediate protein [89]. Also like in the mammalian 
system, CEP-1 activity is controlled by 
post-translational modification. The C. elegans sirtuin 
homolog SIR-2.1 is a deacetylase, and as such is capa-
ble of destabilizing CEP-1 by deacetylating it (pre-
sumably at the C-terminal), significantly affecting 
lifespan (Fig. 18). In both mammalian and yeast sys-
tems, sirtuins are seen to have anti-apoptosis roles, 
and over-expression of sir-2.1 in C. elegans is seen to 
significantly increase lifespan, although it also re-
quires DAF-16 activity [90].  Interestingly, in germ-
line experiments, SIR-2.1 activity was seen to run 
parallel (or possibly upstream) to CEP-1, in inducing 
apoptosis, after DNA damage [90]. This runs counter 
to the deacetylase activity of sirtuins, but is perhaps a 
selective event; only being seen in early apoptotic 
signaling [90]. Generally, though, reductions in cep-1 
expression have been shown to correlate with in-
creases  C. elegans lifespan.  Furthering this, the 
DAF-16 protein, which is active and essential for entry 
into the dauer period, is suspected to repress Cep-1 
transcription [87]. This system is predicted on the 
foundation that lifespan extensions (approximately 
10%) seen with cep-1 RNAi requires daf-16 activity, 
and that CEP-1activity does not inhibit DAF-16 nu-
clear localization [87]. Hence, cep-1 could potentially 
be a downstream target of DAF-16. Along with this, 
there is also thought to be a link between CEP-1 de-
pletion and autophagy, suggesting that the resultant 
lifespan increase with CEP-1 absence is mediated, in 
some fashion, by autophagy [91].  
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Figure 18: The C. elegans p53 ortholog, CEP-1, is stimulated by DNA damage, but can be inhibited by both SIR- 2.1 
(deacetylase) and SCF
FSN-1 (through an unknown). Its transcription factor activity is controlled by post-translational modi-
fication. While the sirtuin like protein, SIR-2.1, can deacetylate and destabilize Cep-1, under certain conditions, it is also seen 
to trigger germline apoptosis; either upstream of or parallel to CEP-1. Int. J. Biol. Sci. 2010, 6 
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The Cell Cycle: Regulation of cellular prolif-
eration and quiescence     
The cell cycle is a complex, highly regulated 
process through which critical events such as aging 
and cellular proliferation (cancer) are affected. The 
standard cell cycle is composed of four stages which 
accomplish goals including DNA replication, segre-
gation of chromosomes and cytokinesis. As illustrated 
in Fig. 19, the cell cycle is typically described as be-
ginning with a gap phase (G1) which then proceeds 
into the DNA synthesis phase (S) and is followed by a 
second gap phase (G2). Subsequently, the cell enters 
the final mitosis (M) phase. The cell cycle can be con-
tinuous or cells may exit from continuous cycling into 
a phase of quiescence (Go), a temporary exit that 
leaves the cycle at the G1 stage (Fig. 19).  
In mammals, cell division and the rate cell divi-
sion rate are largely determined by genetic profile, 
which controls differentiation and transformation 
state. On a protein level, progression of the cell cycle 
is mediated by complexes of cyclin proteins and ‘cy-
clin dependent kinases’ (CDKs) that form maturation 
promoting factors (MPFs). These MPFs, via kinase 
activity, go on to phosphorylate microtubule forming 
proteins and chromatin remodeling complexes, 
amongst others, in order to progress the cell cycle. The 
relationship between specific CDKs and cyclins is 
critical to activate the enzymatic properties of the 
subsequent complex. 
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Figure 19: Basic regulation of the mammalian cell cycle. The cyclin/CDK complexes which act to push the cell cycle across 
the G1/S barrier act primarily on the Rb protein. The complexes themselves are subject to inhibition from CKIs. Rb 
phosphorylation prevents its binding (and inhibition) of E2Fa (activating) transcription factors. It similarly inhibits its activities 
with E2Fr (repressing) transcription factors, which would compete with the E2Fa factors for promoter binding sites on 
critical S phase genes. 
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Typically, cyclins for complexes with specific 
CDKs: cyclin A/B complex with CDK1, cyclin D com-
plexes with CDK4/6, and cyclin E complexes with 
CDK2. These cyclins make the kinases enzymatically 
active, and determine their subcellular locations [92]. 
Cyclins A/B are present and necessary from the time 
a cell enters S phase until cell cycle completion, 
whereas cyclin D and E are primarily involved in 
regulating the G1 phase [92]. The presence and im-
portance of both cyclin D and E in the mammalian G1 
is indicated clearly when these are over-expressed; 
this results in shortened (or accelerated) G1 phases 
[92].  Their requirement in G1 also makes them key 
targets for cell cycle attenuation. There are numerous 
ways in which cyclin activity may be inhibited, but 
two are most common: post-translational modifica-
tion via reversible phosphorylation, and inhibition of 
binding. Phosphorylation of cyclin D, for example, 
may be carried out by glycogen synthase kinase 
(GSK-3) and causes cyclin D export from the nucleus 
(as well as targeting the protein for ubiq-
uitin-mediated degradation) which prevents its asso-
ciations with CDKs [93]. Both cyclin D and E are also 
regulated by inhibitory proteins (see below) which 
bind them (and their respective kinases), preventing 
complex formation. The effects of this type of inhibi-
tion, however, can be reversed by the production of 
additional cyclins, and also in some cases, through 
compensatory activities of cyclin A.  
Blocking the activity of the cyclin/CDK com-
plexes are the so-called CDK inhibitors (CKIs). These 
proteins may be divided into two classes, the ‘inhibi-
tor of CDK4’ (INK4) and the cyclin inhibiting pro-
tein/kinase inhibiting protein (Cip/Kip) families [94]. 
The INK4 group contains four members; p15, p16, p18 
and p19. The INK4 inhibitors function to bind CDK 
4/6 and prevent its association with cyclin D, thereby 
negating its downstream, kinase effects [94]. The 
primary members of the Cip/Kip group are p21, p27 
and p57 and these are disrupters of cyclin D and E 
activity as well as CDKs 2, 4 and 6. Both p27 and 57 
are Kips, whereas p21 is a Cip. These inhibitors func-
tion by binding their targets and preventing their 
downstream enzymatic activities. 
 Whereas both INK4s and Cip/Kips are inhibi-
tors of the cyclin D/CDK4 complex, they may also act 
competitively. The ratio between INK4 bound com-
plexes and Cip/Kip bound complexes varies with the 
amount of INK4 protein present [94]. Displacement of 
Cip/Kips by INK4s releases the Cip/Kips to bind 
cyclinE/CDK2 components, and attenuate the cell 
cycle at the G1 phase. It is this dynamic between the 
two CKI families that also provides the Cips/Kips 
with an interesting dual role with their targets (Fig. 
19). While these proteins can bind cyclin or kinase 
(depending on the family member), to inhibit the 
binding of the other and prevent cyclin/CDK com-
plexing, there are many cases where these CKIs have 
been found bound to active cyclin D/CDK4 com-
plexes. In this sense, the cyclin D/CDK4 complex may 
have a role in sequestering CKI, preventing p27 and 
p21 from inhibiting the cyclin E/CDK2 complex [94].  
Another more interesting role for the Cip/Kip family 
is in aiding the formation of cyclin D/CDK4 com-
plexes. The p21 and p27 proteins are capable of stabi-
lizing cyclin D and CDK4, respectively, in order that 
their complex assembly is promoted [94]. While this 
may appear to further the cell cycle, it is likely a role 
in conjunction with their ability to ‘deliver’ complexes 
for INK4 inactivation. Due to the important role of 
CKIs in regulating the cell cycle, and their own inter-
nal dynamics, they are often the target of cell cycle 
progression proteins, and may be phosphorylated and 
tagged for ubiquitin mediated degradation. However, 
their positive regulation may also be used in order to 
prevent uncontrolled proliferation, illustrating the 
fine level of balance and regulation in the cell cycle. 
The cyclin/CDK, Rb/E2F dynamic in control of 
the cell cycle: 
Within the mammalian cell cycle, the major 
stages of regulation occur at the gap phase barriers 
(G1/S and G2/M), and while many of the same ele-
ments are present at these cross-points, their function 
and necessity may differ. In G1 phase, the primary 
event needed to promote progression into the S phase 
is the phosphorylation of the retinoblastoma protein 
family (Rb; p107 and p130) (Fig. 19). When active, 
these proteins (also known as ‘pocket proteins’) bind 
members of the E2F transcription factor family [95]. 
The E2F family members have binding sites for Rb 
proteins and ‘differentiation regulated transcription 
factor proteins’ (DP), which affect their activity de-
pending on whether they are transcriptional activat-
ing or repressing members of the E2F family. There 
are cases where all three (Rb, DP and E2F (amongst 
others)) form a complex, but this will be covered in 
greater detail later. E2F family members 1-3 (E2F1-3) 
are transcription activators that target genes in order 
to progress the cell cycle into S phase. They are nega-
tively regulated by Rb binding. E2F4 and 5 members, 
however, are transcriptional repressors that competi-
tively bind the same promoter regions of the S phase 
progression target genes [95]. Binding of Rb to the 
repressor E2Fs increases their ability to bind the same 
promoters, and subsequently, signal transcriptional 
repressing (chromatin modeling enzymes) machinery 
[95]. If Rb activity succeeds, then cells may not pro-Int. J. Biol. Sci. 2010, 6 
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gress into the S phase but can instead be held in a 
quiescence phase (Go).  
Hence, the regulation of the Rb/E2F dynamic is 
seen throughout the cell cycle, but is of notable im-
portance at the G1 phase. With phosphorylation of the 
Rb protein causing unbinding from the transcription 
factor, it is the cyclin/CDK complexes that determine 
its activity. While both cyclin E/CDK2 and cyclin 
D/CDK4 complexes are able to phosphorylate Rb, it is 
suspected that cyclin D/CDK4 is primarily responsi-
ble. In double-knockouts of CDK 2 and 4, using 
mouse embryo fibroblasts (MEFs), a steady loss in Rb 
phosphorylation was duly seen, resulting in de-
creased E2F target transcription, including that of 
CDK1 (which can be an upstream inhibitor of Rb) [96]. 
A positive feedback loop in this circuit leads to the 
induction of cyclin E transcription by the E2Fs, which 
in turn bind and activate CDK2 for Rb phosphoryla-
tion.  
While their seemingly critical role in the regula-
tion of the cell cycle would suggest against it, the 
presence of all cyclins and CDKs are not necessary for 
cellular replication. For example, cyclins D and E do 
not seem to be required in embryonic cells in mam-
malian systems, neither was the presence of the cyclin 
D/CDK4 complex in embryonic stem cells [96]. In 
numerous mouse knockout models it was discovered 
that CDK4/6 was not necessary to complete the cell 
cycle [96]. The absence of CDK4 caused a 4 hour delay 
in S phase entry, but this was suspected to be a result 
of impaired cyclin E/CDK2, via uninhibited p27 ac-
tivity. It was subsequently shown through CDK4/p27 
double mutants that CDK2 activity and the S phase 
entry were restored [96].  Similar to the condition of 
CDK4 absence, were the results of CDK2 mutations, 
which also caused a 4 hour delay in S phase entry but 
did not prevent cell cycle progression. It is suspected 
that CDK1 takes the role of ‘cyclin E binding partner’, 
allowing the cell to pass the G1/S barrier [96]. Com-
bined, this indicates that the specifics of cyclin/CDK 
presence at given stages may show functional re-
dundancy, but also maybe indicative of recovery or 
compensatory mechanisms when these proteins are 
targeted for inhibition. 
Post-translational control of the cell cycle: 
Control of the cell cycle is heavily regulated by 
post-translational modifications (Fig. 20). Cyclins are 
phosphorylated and ubiquitinated for degradation, 
Rb is phosphorylated by cyclin/CDK complexes and 
dissociated from E2Fs. The CDKs are also subject to 
regulation via phosphorylation. The highly conserved 
Wee family of kinases (originally discovered in 
Schizosaccharomyces pombe; including Wee1, 2 and 
Myt1) is involved in phosphorylating threonine and 
tyrosine residues of the ‘cell division cycle’ 2 (Cdc2) 
and CDKs [96]. Like the CDKs, Cdc2 forms complexes 
with cyclins (A and B) to initiate mitosis, and is 
phosphorylated (at Tyr15) and inactivated by Wee1. 
Similarly, CDK2 may be phosphorylated on both 
Tyr15 and Thr14, likely in order to regulate the G1/S 
transition [97]. Counteracting these inhibitory phos-
phorylations is dephosphorylation mediated by the 
cdc25 phosphatase. These cyclin/CDK complex acti-
vators are able to dephosphorylate both Tyr15 and 
Thr14 residues, and are commonly seen to be 
over-expressed in human cancers, making them vi-
able drug targets [98]. The cdc25 phosphatases not 
only act to repress inhibitory phosphorylation, but are 
targets of it themselves. DNA checkpoints in the cell 
cycle preserve accurate replication and report DNA 
damage. The key kinases in these checkpoints, in-
cluding ATM kinase, activate downstream checkpoint 
kinases (Chks), which often act to stop the cell cycle 
from progressing, allowing repairs to be made (Fig. 
20) [99]. Specifically, Chk1 can inhibit cdc25 via 
phosphorylation of a c-terminal residue (at a ho-
mologous site to a human 14-3-3 binding site). This 
phosphorylation inactivates cdc25, and while it is not 
required for inhibition, may recruit 14-3-3 proteins to 
sequester the phosphatases (see previous discussion 
of 14-3-3 proteins) [99].  This system of phosphoryla-
tion control occurs across organisms, indicating a high 
level of conservation and importance in cell cycle 
regulation.    
While there are numerous cell cycle inhibiting 
proteins, there are also targets which seek to enhance 
cell cycle progression. The oncogenic activity of c-Myc 
which seeks to create cellular proliferation through 
increased cell cycle activity, acts at the G1/S barrier. 
Like over-expression of the cyclins D and E, 
over-expression of c-Myc results in a shortened G1 
profile. This is suspected to be due to gene targets that 
it up-regulates in order to progress to the DNA repli-
cation phase; targets that may include cyclin D, p21 
and E2F2 [100]. In mammalian (rat) cell lines, it was 
subsequently shown that the absence of c-Myc sig-
nificantly reduces cyclin D/CDK4 activity, which in 
turn delays the formation of CDK2 complexes [100]. 
The absence of c-Myc was also notably correlated 
with an increase in the p27 kinase inhibiting protein 
[100]. Thus, as in other systems controlling prolifera-
tion, c-Myc is seen to exert its influence (Fig. 20). In-
terestingly, like many other components regulating 
the cell cycle, c-Myc has a role in apoptosis stimula-
tion and is subsequently, negatively regulated by 
E2F1. Protein kinase B (Akt), is signaled by E2F1 over 
expression, and inhibits the signaling of target apop-Int. J. Biol. Sci. 2010, 6 
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tosis proteins by c-Myc [101]. E2F1 has its own apop-
totic functions, which are also interestingly regulated 
by Akt, via up-regulation of the DNA binding topoi-
somerase II β binding protein (TopBP1) [101]. 
The variation and regulation of the C. elegans cell 
cycle: 
The C. elegans model has been invaluable in the 
study of the cell cycle. The ease of culturing, ability to 
isolate the different replication cycle phases, and the 
application of genetic manipulation has helped dis-
cover a number of firsts in cell cycle regulation. Cell 
cycle regulation in C. elegans is defined by the type of 
cell; embryonic, somatic, endoreduplication, and 
meiotic. Each of these cell types, while largely un-
dergoing the same processes, can differ in cell cycle 
profile.  Embryonic lines, for example, lack the gap 
phases, and as such do not require the regulatory 
controls on these stages [102]. Similarly, the endore-
duplication cycles are without mitosis, following 
DNA replication [102]. The somatic cells, however, 
undergo the full cell cycle, which means that controls 
in these cells are most similar to mammalian controls. 
Cell cycle control in nematodes is again primar-
ily influenced by the activities and regulation of cy-
clin/CDK complexes (Fig. 21). In C. elegans, there are 
both cyclin E and D homologs (CYE-1 and CYD-1, 
respectively) as well as a CDK4 homolog (CDK-4). 
Currently, no definite C. elegans CDK2 homolog is 
known, but a likely candidate gene (k03e5.3) with 
~40% amino acid homology to the human protein, has 
been identified [104]. Also similar to mammalian cell 
cycle regulation is the presence of CKIs such as ho-
mologs of the p27 kip (CKI-1), Myt1/Wee-1 kip 
(WEE-1.3) and critical regulating phosphatases Cdc25 
and 14 (CDC-25.1 and CDC-14) (Fig. 21) [102, 104]. 
Once again, the G1/S phase and G2/M barriers are 
critical targets of regulation via the cyclin/CDK com-
plexes. Whilst there are members of the C. elegans 
CDK family that are involved in multiple phases of 
the cell cycle, like CDK-1, there are also stage specific 
interactions like the cyclin/CDK complexes, which 
again mirrors mammalian systems.   
C-Myc
E2F1
Akt
JNK p38
ASK-1
TOPB1
E2F2 p21
GSK3
Cell 
Cycle
M
G1
S
G2
Go
D
p21
p27
ARK
ATM
Chk-1
cdc25
CDK
cyc
Wee1
Rb
Rb
P
D
DNA damage
Apoptosis
Apoptosis
S-Phase 
progression
Transcriptional regulation
= Cell cycle 
progression
= Cell cycle inhibition
= c-Myc related 
activity
= Apoptosis 
signaling/ inhibition
 
Figure 20: Reversible phosphorylation regulation of the cell cycle. Cyclin/CDK complexes may be inactivated through 
phosphorylation, mediated by the Wee kinase family. Phosphorylation may be reversed by the Cdc-25 phosphatase. This 
phosphatase may also be inactivated through Chk-1 mediated phosphorylation. DNA checkpoint kinases are regulated by 
the ATM kinase, which in turn may receive signals from DNA damage and the insulin response pathway. The Akt kinase of 
the insulin signaling pathway, phosphorylates numerous cell cycle targets, including Cip/Kips and GSK-3 (which targets cyclin 
D). Int. J. Biol. Sci. 2010, 6 
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Figure 21: Regulation in the C. elegans cell cycle. Like the mammalian system, the primary role of the cyclin/CDK complexes 
is to phosphorylate the retinoblastoma protein (LIN-35), which negatively regulates S-phase progression genes. The cy-
clin/CDK complexes are susceptible to phosphorylation (which can be reversed by CDC-25.1) and inhibition by CKIs, which 
act to attenuate the cell cycle. 
 
 
In the embryonic cycle, while there are no gap 
phases, interactions between cyclins and CDKs still 
regulate completion. The absence of cyclins A and B, 
which typically interact with CDK-1, was tested using 
RNAi. The resultant arrest in embryonic cell division 
indicated that these cyclin/CDK complexes are nec-
essary to prevent cell cycle attenuation [102]. Because 
of its role in the G1 phase, the CYD-1/CDK-4 complex 
is not often seen in embryonic cell development [102], 
but post embryonic development, the necessity of 
cyclin D/CDK4 (CYD-1/CDK-4) complexes becomes 
apparent.  
 The G1 phase, critical in cell cycle regulation in 
many models, integrates a number of signals; includ-
ing the cyclin/CDKs, their cyclin/kinase inhibitors, 
retinoblastoma proteins and E2F transcription factors, 
and microRNAs. In identifying C. elegans cell cycle 
regulators, vulval cells have contributed significantly.  
Part of this is due to the cell cycle attenuation, or in 
this case quiescence, that occurs throughout the L1 
and 2 larval stages, and only resumes mid-way 
through the L3 stage, which makes them an intriguing 
model of regulation [103].  Of the vulval cell types, a 
number of critical cell cycle regulators were discov-
ered in the ‘multivulva’ (Muv) phenotype [104]. The 
Muv phenotype requires the expression of multiple 
classes of ‘synthetic’ multivulva genes (synMuv), and 
amongst these (synMuv class B) were discovered a 
number of critical genes that associate together to 
regulate the cell cycle (Fig. 21). The retinoblastoma 
(pRB) family of tumor suppressors (mentioned above) 
is represented in the ‘abnormal cell lineage’ 35 
(LIN-35) protein, acting as a C. elegans p107 homolog 
[102]. The E2F family of transcription factors are also 
represented through the E2F family like (EFL-1) pro-
tein, which closely resembles the transcription inhib-
iting E2F4. Another known factor to associate with 
pRb is the ‘differentiation-regulated transcription 
factor 1 polypeptide’ or DP-like protein (DPL-1) [95].  
As in mammalian G1 regulation, the role of Int. J. Biol. Sci. 2010, 6 
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nematode CYD-1/CDK-4 appears to function primar-
ily in regulating cell cycle attenuators, and not spe-
cifically in cell cycle development. By inhibiting the 
Cip/Kip CKI-1 and LIN-35, the CYD-1/CDK-4 com-
plex allows the CYE-1/CDK-2 to function, and propel 
the cell cycle into the S phase [104]. Through the use of 
RNAi, it was revealed that while both lin-35 and efl-1 
individually have disruptive effects on G1 progres-
sion, and when their deletion was put in conjunction 
with a cki-1 deletion, the resultant increase in cellular 
proliferation was far greater [104]. This earmarks the 
Cip/Kip homolog, CKI-1 as the likely controlling 
factor in G1/S phase progress.  In regards to this, the 
promoter region of the cki-1 gene has numerous 5’ 
upstream sequences, which would allow the gene to 
be regulated by multiple signals [104]. In vulval pre-
cursor cells (VPCs), the cki-1 promoter region was 
found to have over 20 consensus binding sites for ETS 
and forkhead box transcription factors [103].  
Signaling and interactions between the cy-
clin/CDKs and CKIs are typically done through 
post-translational modification, using phosphoryla-
tion as a means of altering protein conformation, and 
as a result, activity. Hence dephosphorylation, 
through cell cycle phosphatases, CDC-25 and 14, is of 
equal importance.  These two major cell cycle phos-
p h a t a s e s  w o r k  i n  o p p o s i t i o n  t o  e a c h  o t h e r ,  w i t h  
CDC-25 maintaining active cyclin/CDKs, and 
CDC-14 acting upstream of CKIs to maintain their 
activity. In C. elegans, the cdc-25 phosphatase has four 
members (CDC-25.1-4), and dephosphorylates cy-
clin/CDK complexes that have been phosphorylated 
(and inactivated) by the Wee1/Myt kinase homolog, 
WEE-1.3 [102]. It is suspected that WEE-1.3 primarily 
targets CDK-1 (from mutational data), but the C. ele-
gans CDK-2 (K03E5.3) contains a similar ATP binding 
site that may also be negatively regulated by phos-
phorylation [102]. The CDC-14 phosphatase on the 
other hand, is suspected to maintain CKI-1 stability by 
dephosphorylating it, stimulating cell cycle arrest. It is 
thought that CKIs, from mammalian to C. elegans, are 
targeted by ubiquitin for proteasomal degradation, 
after being phosphorylated [104].   
The DREAM/DRM complex and its role in de-
velopment: 
A further similarity to the mammalian system, 
but on the periphery of core cell cycle regulation, is 
the complexing of C. elegans Rb related proteins. 
Complex initiation, which likely begins with a het-
erodimerization between EFL-1 and DPL-1 proteins, 
later aggregates with LIN-35. This trimer, along with 
other myeloblastosis (MYB) proteins (which them-
selves are able to regulate cell prolifera-
tion/differentiation), forms what is known as the 
DREAM complex (C. elegans DRM) [95]. DREAM 
complexes are suspected to manipulate chromatin in 
order to regulate transcription of specific genes. 
Whereas the mammalian model of the DREAM com-
plex is thought to directly target promoter regions of 
developmental genes, the C. elegans DRM complex is 
thought to possibly act in conjunction with the nu-
cleasome remodeling and deacetylase (NuRD) com-
plexes; in order to regulate chromatin structure of 
epidermal growth factors (EGFs) (Fig. 21) [95]. Con-
sequently, this would regulate Ras/EGF recep-
tor/MAPK pathways. Interestingly, while the 
LIN-35/EFLl-1/DPL-1 complex is likely to repress 
transcription, the DPL-1 protein is thought to also 
complex an activating transcription factor member of 
the E2F family in order to promote the S phase [104]. 
Like many cell cycle regulators, the DPL-1 protein has 
the capacity to both progress the cell cycle and initiate 
apoptosis. For example, DPL-1 can also promote the 
expression of ced-4 and 3, which are caspase activator 
and caspase homologs, respectively.  
The combined activities of LIN-35 (including its 
associated factors) and CKI-1 result in an attenuation 
of the cell cycle at the G1/S phase, but they are not the 
only members to cause arrest at this stage. The ab-
normal cell lineage members 19 and 23 (re-named for 
the ‘cullin’ gene family, cul-1, and lin-23, respectively) 
encode for members of the ubiquitin ligase complex, 
which would be able to degrade G1/S phase regula-
tors [102]. The Skp-1-Cul1-Fbox (SCF) complex par-
ticularly targets CYE-1. The cullin family, with six 
members in C. elegans, is involved in the degradation 
of numerous proteins; specifically those involved in 
cell cycle progression. Targets include mei-1 (involved 
in microtubule severing which allows chromosome 
segregation) and cdt (involved in DNA replication), 
which, if active could allow the progression and 
completion of the cell cycle [102]. 
Developmentally, apoptosis is necessary for C. 
elegans at the embryonic and L2 larval stages, and as 
seen through many of the regulators of the cell cycle 
(and throughout the preceding sections) apoptosis 
and proliferation mediation are often closely linked. 
Apoptosis mediates the removal of muscular, hypo-
dermal, reproductive (egg) and neuronal cells, when 
necessary, to promote development. The cells targeted 
for apoptosis subsequently exhibit cell cycle arrest 
prior to cell death. Thus, it comes as little surprise that 
the C. elegans p53 tumor suppressor homolog, CEP-1, 
interacts with the cell cycle machinery. DNA check-
points ensure that DNA is properly replicated, as well 
as undamaged, and are able to arrest the cell cycle if 
its conditions are not met [102]. In the germline, Int. J. Biol. Sci. 2010, 6 
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genotoxic stress can induce CEP-1 mediated apop-
tosis, and can also regulate cellular proliferation. 
CEP-1 is suspected to be an upstream activator of the 
cell cycle associated phg-1 (a C. elegans  ‘Growth Ar-
rest-Specific1’ (GAS1) equivalent) [105]. Upstream of 
this relationship, the CLK-2 protein, in C. elegans, is 
essentially an S-phase checkpoint regulator, which is 
suspected to transmit DNA damage signals to CEP-1 
(and PHG-1), and resultantly control rates of prolif-
eration and DNA repair [105]. Another example of 
checkpoint control in C. elegans can be seen in the 
germline of mature hemaphroditic adults, in 
pre-oocyte cells (Pachytene stage germ cells). These 
cells routinely undergo apoptosis, and in response to 
checkpoint signaling (via MRT-2 and HUS-1), CEP-1 
activity is triggered [106]. Downstream, CEP-1 acti-
vates pro-apoptotic BH3-only proteins (EGL-1 and 
CED-13), which allows the expression of caspases 
(ced4 and 3) via inhibition of anti-apoptotic proteins 
(primarily CED-9). Interestingly, parallel to this, 
LIN-35 (via ced-9 inhibition), EFL-1 and DPL-1(both 
via  ced4/3 activation) may also be involved in 
pre-oocyte apoptosis [106].   
The novel role of mirco RNAs in metabolic 
regulation: 
Whereas the patterns of cell cycle regulation, in 
terms of the key proteins, are fairly well conserved 
and understood from C. elegans to mammalian sys-
tems, the fairly novel role of micro RNAs (miRNA) in 
transcriptional regulation has proven to have sub-
stantial effects on the cell cycle. Micro RNAs, first 
discovered in C. elegans, are short (approximately 
20-25nt) RNA sequences that repress gene expression 
by binding to 3’ untranslated regions (UTRs) of target 
mRNAs to prevent their translation [107]. Once 
bound, the miRNAs aggregate with other protein 
members of a ‘RNA-induced silencing complex’ 
(RISC). This can signal RNase activity, which cleaves 
the target mRNA, nullifying its expression. Micro 
RNAs are highly conserved across species and have 
been found to be involved in numerous critical cellu-
lar processes such as the regulation of metabolism, 
apoptosis signaling and, relevant here, cell cycle con-
trol [107]. Whereas miRNAs can function in clusters, 
their regulation patterns are individual, despite often 
having common (larval) stage specific expression 
patterns with the other members of the complex. 
There are hundreds of identified miRNAs, each able 
to affect multiple mRNA targets, which indicates that 
miRNAs are major players in cellular regulation. 
Although some miRNAs are suspected of par-
ticipating in cellular ‘housekeeping’ functions, others 
show patterns of up-regulation at significant devel-
opmental transitions such as from L1 to L2, and L4 to 
the mature adult stages of C. elegans larval develop-
ment, respectively [108]. These include lin-4 and let-7. 
The let-7 family of miRNAs, along with the 
miR-15a/16-1 cluster, has recently come to light as 
important regulators of the cell cycle and tumor sup-
pression, from C. elegans to human systems.  The 
tumor suppressing capacities of let-7 in human mod-
els have significant implications in cancer research, 
with deletions of let-7 producing loci seen in many 
cancers [108]. Let-7 has numerous targets, including 
the c-Myc oncogene, CDK6 and CDC25A. Regulation 
of the cell cycle members would prevent progression 
in both G1/S and G2/M phases, and indeed 
over-expression of let-7 resulted in an accumulation of 
cells in the quiescence (Go) phase [108]. Similarly, en-
forced expression of miR-16 (which also targets 
CDK6) results in cells accumulating in the Go phase. 
Along with the cyclin dependent kinases, miRNAs 
have also been seen to target their inhibitors; the 
Cip/Kip family of proteins. One of the major G1/S 
phase regulating CKIs, p27, is regulated in mammal-
ian systems by the miR-221/miR-222 cluster. Along 
with p27, p21 is also suspected to be regulated by 
miRNAs, the miR-17 family, in response to a p53 me-
diated cell cycle arrest signal which uses p21 to me-
diate the arrest [108]. Recently, it has been shown that 
members of the ‘inhibitors of CDK4’ (INK4), p15, p16, 
p18 and p19 can be regulated by miRNAs (notably 
p16 can be repressed by miR-24), and the absence of 
miRNA regulation of p27 by miR-221/222 has been 
linked to tumorigenesis [108]. Hence, regulation of 
CKIs by miRNAs, appears to be an important step in 
G1/S phase progression, and as such has possible im-
plications in cancer development.   
The miRNA interaction with c-Myc, alluded to 
briefly, above, affects the positive relationship be-
tween c-Myc and the activating E2Fs, which if left 
unregulated may lead to apoptosis (through excess 
proliferation signals), and as such, is a target for inhi-
bition. In a feed-forward inhibition mechanism, c-Myc 
is also able to activate the expression of the miR17-92 
complex of miRNAs, which in turn inhibits the trans-
lation of E2F1-3 genes [108]. Similarly, the E2F1 tran-
scription factor is able to repress its own translation, 
to prevent excess cell proliferation, via the activation 
of the miR-106b-25 complex. The Rb proteins are also 
targeted by miRNAs to affect their interactions with 
the E2Fs. The p130 member, which typically binds the 
repressor E2F4, may be direc t l y  t a r g e t e d  b y  m i R 1 7  
[108]. Subsequently, it is down-regulated, which in-
dicates that miR17 may act to promote G1 progression.     Int. J. Biol. Sci. 2010, 6 
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Conclusion 
Studies with C. elegans provide the most detailed 
and comprehensive information about the biochem-
istry and molecular biology involved in regulating 
dormancy in a eukaryote. The signaling and regula-
tory mechanisms described in this review suggest the 
blueprint for transitioning into a hypometabolic state 
and the “balancing act” between three states: 
growth/development, stasis/life extension, and deg-
radation. They illustrate the intricacies of regulatory 
responses to nutrient and environmental stresses and 
the wide-ranging interactions that have to be consid-
ered when planning a coordinated suppression of 
cellular metabolism that achieves homeostasis and life 
extension over long periods of time spent in dor-
mancy. From studies to date we know that many 
principles of metabolic arrest are conserved across 
phylogenetic lines; from  controlling energetic ex-
penditure via post-translational control of glycolytic 
proteins and ATPases, to protein-protein and pro-
tein-DNA interactions regulating cellular prolifera-
tion and apoptosis. The C. elegans model suggests ad-
ditional mechanisms that could be fundamental prin-
ciples of metabolic suppression across phylogeny and 
gives us many new roads to explore to determine the 
common and disparate mechanisms that underlie 
hypometabolism in its many forms. Similarly, with C. 
elegans as a marker for other models of hypometabo-
lism, new avenues of regulation to conditions such as 
ischemia/reperfusion damage, insulin resistance, 
neurodegenerative diseases and cancer are opened to 
us in the search for modern clinical treatments.  
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